WO2015147834A1 - Bioactive glass and collagen combination products and kits - Google Patents

Bioactive glass and collagen combination products and kits Download PDF

Info

Publication number
WO2015147834A1
WO2015147834A1 PCT/US2014/032035 US2014032035W WO2015147834A1 WO 2015147834 A1 WO2015147834 A1 WO 2015147834A1 US 2014032035 W US2014032035 W US 2014032035W WO 2015147834 A1 WO2015147834 A1 WO 2015147834A1
Authority
WO
WIPO (PCT)
Prior art keywords
bioactive glass
glass
collagen
combination product
bioactive
Prior art date
Application number
PCT/US2014/032035
Other languages
French (fr)
Other versions
WO2015147834A8 (en
Inventor
Gregory J. Pomrink
Zehra TOSUN
Cecilia CAO
Joshua Clark
Original Assignee
Novapone Products, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novapone Products, Llc filed Critical Novapone Products, Llc
Priority to CA2943837A priority Critical patent/CA2943837A1/en
Priority to AU2014388329A priority patent/AU2014388329B2/en
Priority to EP14886709.6A priority patent/EP3122392A4/en
Priority to PCT/US2014/032035 priority patent/WO2015147834A1/en
Publication of WO2015147834A1 publication Critical patent/WO2015147834A1/en
Publication of WO2015147834A8 publication Critical patent/WO2015147834A8/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/42Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
    • A61L27/425Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/06Flowable or injectable implant compositions

Definitions

  • Collagen is the main component of connective tissue and is generally found in the body as a triple helix. Collagen is also prevalent in bone.
  • Known methods of crosslinking include introducing disulfide bonds between individual collagen molecules and fibrils.
  • Crosslinked collagen can have enhanced mechanical attributes. The addition of crosslinked collagen to wounded tissue or bone defects may serve to provide structural support.
  • Bioactive glass was originally developed in 1969 by L. Hench. Additionally bioactive glasses were developed as bone replacement materials, with studies showing that bioactive glass can induce or aid in osteogenesis. Hench et al, J. Biomed. Mater. Res. 5:1 17-141 (1971 ). Bioactive glass can form strong and stable bonds with bone. Piotrowski et al., J. Biomed. Mater. Res. 9:47-61 (1975). Further, bioactive glass is not considered toxic to bone or soft tissue from studies of in vitro and in vivo models. Wilson et al., J. Biomed. Mater. Res. 805-817 (1981 ).
  • Exemplary bioactive glasses known in the art include 45S5, 45S5B1 , 58S, and S70C30.
  • the original bioactive glass, 45S5, is melt-derived.
  • Sol-gel derived glasses have nanopores that allow for increased surface area and bioactivity.
  • U.S. Patent Application Publication No. 2002/0055143 discloses cement particles UV crosslinked with collagen.
  • U.S. Patent No. 8,252,055 discloses crosslinking a collagen mineral containing composition including Bioglass.
  • One aspect of the invention provides for a method for crosslinking collagen.
  • An ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is freeze-dried to form a composite.
  • Another aspect of the invention provides for a method for crosslinking collagen fibers.
  • Water or an ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is freeze-dried to form a composite.
  • the composite is immersed in water or solutions containing divalent or polyvalent metal ions.
  • the composite is freeze-dried.
  • Yet another aspect of the invention provides for a method for crosslinking collagen.
  • An ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is transferred to a mold.
  • the paste is freeze-dried to form a composite.
  • Another aspect of the invention provides for a method for crosslinking collagen fibers.
  • Water or an ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is freeze-dried to form a composite.
  • the composite is immersed in water or solutions containing divalent or polyvalent metal ions.
  • the composite is freeze-dried and then dried.
  • An aspect provides for a mixture of collagen and a glass.
  • the mixture comprises from 60 wt.% to 90 wt.% of the glass.
  • the collagen is crosslinked by the glass.
  • the mixture does not comprise chitosan or an organic crosslinking agent.
  • the invention also provides for a crosslinked collagen material consisting of collagen and a glass. Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen, water, and a glass. Alternatively, the invention provides for a crosslinked collagen material consisting of collagen, an ion-containing solution, and a glass. [0012] The invention also provides for a crosslinked collagen material consisting of collagen fibers and a glass. Alternatively, the invention provides for a crosslinked collagen material consisting of collagen fibers, water, and a glass. Another aspect of the invention provides for a crosslinked collagen material consisting of collagen fibers, an ion-containing solution, and a glass.
  • the invention provides for a combination product that includes a porous and nonporous bioactive glass and collagen.
  • the bioactive glass may be present in a weight ratio of from 80% to 97% in proportion to the total weight of the bioactive glass and the collagen.
  • the combination product may include from 85 wt.% to 97.5 wt.% of the bioactive glass.
  • the combination product may be in a form of a packable graft.
  • the packable graft may include 75-95 wt.% bioactive glass and 5-25 wt.% collagen.
  • the packable graft may include 85 wt.% bioactive glass and 15 wt.% collagen.
  • the bioactive glass may include 55-65% 1000- 2000 um bioactive glass, 10-20% 90-710 um bioactive glass, and 10-20% 32-125 um bioactive glass.
  • the bioactive glass may include 60% 1000- 2000 um bioactive glass, 12.5% 90-710 um bioactive glass, and 12.5% 32-125 um bioactive glass.
  • the 1000-2000 um bioactive glass is porous.
  • the combination product may be in a form of a collagen bioactive glass composite.
  • the composite may include 75-95 wt.% bioactive glass and 5-25 wt.% collagen.
  • the composite may include 90 wt.% bioactive glass and 10 wt.% collagen.
  • the bioactive glass of the composite may include 55-65% 1000-2000 um bioactive glass, 10-20% 90-710 um bioactive glass, and 10-20% 32-125 um bioactive glass.
  • the bioactive glass of the composite may include 60% 1000-2000 um bioactive glass, 15% 90-710 um bioactive glass, and 15% 32-125 um bioactive glass.
  • the 1000-2000 um bioactive glass of the composite is porous.
  • the combination product may be in a form of a strip.
  • the strip may include 85-97 wt.% bioactive glass and 3-15 wt.% collagen.
  • the strip may include 95 wt.% bioactive glass and 5 wt.% collagen.
  • the strip may include 97.5 wt.% bioactive glass and 2.5 wt.% collagen.
  • the bioactive glass of the strip may include 53.5-73.5% 1000-2000 um bioactive glass, 10-20% 90-710 um bioactive glass, 10-20% 32-125 um bioactive glass.
  • the bioactive glass of the strip may include 63.33% 1000-2000 urn bioactive glass, 15.83% 90-710 urn bioactive glass, 15.83% 32-125 um bioactive glass.
  • the 1000-2000 um bioactive glass of the strip is porous.
  • the bioactive glass may include 64.68% 1000-2000 micrometer bioactive glass, 16.16% 90-710 micrometer bioactive glass, 16.16% 32-125 micrometer bioactive glass.
  • the combination product may further include at least one therapeutic agent, protein, or glycosaminoglycan.
  • kits comprising a combination product in a form of a packable graft, composite or a strip and a packaging.
  • the packaging may be a double peel packaging.
  • the packaging may include an inner tray, wherein the combination product is contained within the inner tray, an inner tray lid, an outer tray, wherein the inner tray is placed in the outer tray, and an outer tray lid.
  • the kit may further include a dispenser box.
  • the kit may further include a syringe.
  • the combination product may be disposed within the syringe.
  • the syringe may include a removable cap.
  • the syringe may be placed in the inner tray.
  • the kit may include a syringe comprising a removable cap, wherein the syringe is sealed in a pouch.
  • the invention provides for a method for ionically crosslinking collagen.
  • the method includes mixing an ion-containing solution with the 10 wt.% collagen and 90 wt.% bioactive glass to form a paste and freeze-drying the paste to form a composite.
  • Figure 1 is a photomicrograph of crosslinked collagen bioactive glass strip composite at 29.9x magnification.
  • Figure 2 is a photomicrograph of crosslinked collagen bioactive glass strip composite at 300x magnification.
  • Figure 3 depicts a graph of blood absorption of Bioactive Strip, Composite and Packable products.
  • Figures 4 A-B are photographs depicting a CBG composite product and its packaging.
  • Figure 4C is a photograph of the CBG composite product combined with a fluid.
  • Figure 4 D depicts a photograph of an exemplary dispenser box.
  • Figure 5 depicts a bar graph showing the average porosity of MacroFORM
  • Figure 6A is a photograph of the dry form of the exemplary CBG strip placed in its packaging.
  • Figure 6B is a photograph of the exemplary CBG strip in its packaging during hydration with blood.
  • Figure 6C is a photograph of the exemplary CBG strip in a hydrated state.
  • Figure 6D is a photograph of the exemplary CBG strip in a hydrated state.
  • Figures 7A-C are photographs of the dry form of the exemplary CBG strip placed in its packaging.
  • Figure 8 is a photograph of the exemplary inner and outer trays of the packaging for the CBG strips.
  • One aspect of the invention provides for a method for crosslinking collagen.
  • An ion-containing solution is mixed with the collagen and bioactive glass to form a paste.
  • the paste is freeze-dried to form a composite.
  • the method further comprises drying the composite. These steps may be performed in succession or in any order.
  • One way in which the composite may be dried is by dehydrothermal treatment.
  • Significant crosslinking of the collagen can occur without any drying step or dehydrothermal treatment step undertaken. Addition of the drying step or dehydrothermal treatment step can lead to enhanced crosslinking.
  • Bioactive glass used in the invention may be melt-derived or sol-gel derived. Depending on their composition, bioactive glasses of the invention may bind to soft tissues, hard tissues, or both soft and hard tissues.
  • the composition of the bioactive glass may be adjusted to modulate the degree of bioactivity.
  • borate may be added to bioactive glass to control the rate of degradation.
  • Additional elements, such as barium, copper, fluorine, silver, zinc, and strontium may be added to bioactive glass to facilitate healthy bone growth or provide other desirable properties.
  • the bioactive glass may be in the form of a particle, a glass sheet, a fiber, a mesh, or any combination of these forms.
  • Bioactive glass is capable of bonding to bone, which begins with the exposure of bioactive glass to aqueous solutions.
  • Sodium ions in the glass can exchange with hydronium ions in body fluids, which increases the pH.
  • Calcium and phosphorous ions can migrate from the glass to form a calcium and phosphate-rich surface layer.
  • Borate ions can also migrate from the glass to from a surface layer rich in boron.
  • Strontium ions also can migrate from the glass to form a strontium-rich surface layer. Underlying this surface layer is another layer which becomes increasingly silica rich due to the loss of sodium, calcium, strontium, boron, and/or phosphate ions (U.S. Pat. No. 4,851 ,046).
  • Hydrolysis may then disrupt the Si-O-Si bridges in the silica layer to form silanol groups, which can disrupt the glass network.
  • the glass network is then thought to form a gel in which calcium phosphate from the surface layer accumulates. Mineralization may then occur as calcium phosphate becomes crystalline hydroxyapatite, which effectively mimics the mineral layer of bones.
  • Bioactive glass particles, fibers, meshes or sheets may be prepared by a sol- gel method. Methods of preparing such bioactive active glasses are described in Pereira, M. et al., "Bioactive glass and hybrid scaffolds prepared by sol-gel method for bone tissue engineering” Advances in Applied Ceramics, 2005, 104(1 ): 35-42 and in Chen, Q. et al., "A new sol-gel process for producing Na 2 O-containing bioactive glass ceramics” Acta Biomaterialia, 2010, 6(10):4143-4153.
  • the composition can be allowed to solidify.
  • particles of bioactive glass are sintered to form a porous glass.
  • a glass drawing apparatus may be coupled to the spinner and the source of molten bioactive glass, such as molten bioactive glass present in a crucible, for the formation of bioactive glass fibers.
  • the individual fibers can then be joined to one another, such as by use of an adhesive, to form a mesh.
  • the bioactive glass in molten form may be placed in a cast or mold to form a sheet or another desired shape.
  • the bioactive glass particles, fibers, meshes or sheets may further comprise any one or more of adhesives, grafted bone tissue, in vitro-generated bone tissue, collagen, calcium phosphate, stabilizers, antibiotics, antibacterial agents, antimicrobials, drugs, pigments, X-ray contrast media, fillers, and other materials that facilitate grafting of bioactive glass to bone.
  • a bioactive glass ceramic material suitable for the present compositions and methods may have silica, sodium, calcium, strontium, phosphorous, and boron present, as well as combinations thereof.
  • sodium, boron, strontium, and calcium may each be present in the compositions in an amount of about 1 % to about 99%, based on the weight of the bioactive glass ceramic.
  • sodium, boron, strontium and calcium may each be present in the composition in about 1 %, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%.
  • silica, sodium, boron, and calcium may each be present in the composition in about 5 to about 10%, about 10 to about 15%, about 15 to about 20%, about 20 to about 25%, about 25 to about 30%, about 30 to about 35%, about 35 to about 40%, about 40 to about 45%, about 45 to about 50%, about 50 to about 55%, about 55 to about 60%, about 60 to about 65%, about 65 to about 70%, about 70 to about 75%, about 75 to about 80%, about 80 to about 85%, about 85 to about 90%, about 90 to about 95%, or about 95 to about 99%.
  • Some embodiments may contain substantially one or two of sodium, calcium, strontium, and boron with only traces of the other(s).
  • Divalent cations or ions that may be present in any of the bioactive glasses of this and other aspects of the invention include one or more of iron-ll, iron-Ill, alumina, chromate, cobalt, tin, copper, magnesium, and zinc.
  • the bioactive glass materials may further comprise one or more of a silicate, borosilicate, borate, strontium, or calcium, including SrO, CaO, P2O 5 , SiO 2 , and B 2 O 3 .
  • An exemplary bioactive glass is 45S5, which includes 46.1 mol% SiO 2 , 26.9 mol% CaO, 24.4 mol% Na2O and 2.5 mol% P2O 5 .
  • An exemplary borate bioactive glass is 45S5B1 , in which the S1O2 of 45S5 bioactive glass is replaced by B2O3.
  • bioactive glasses include 58S, which includes 60 mol% S1O2, 36 mol% CaO and 4 mol% P 2 O 5 , and S70C30, which includes 70 mol% SiO 2 and 30 mol% CaO.
  • SrO may be substituted for CaO.
  • compositions having a weight % of each element in oxide form in the range indicated, will provide one of several bioactive glass compositions that may be used to form a bioactive glass ceramic:
  • the particles are sintered to form porous particulate made from the bioactive glass particles.
  • fine particles of the bioactive glass are mixed with a sacrificial polymer and a binder to create a pre-shaped construct (e.g., a block or disk).
  • the construct is then heated under specific conditions that allow a welding of the particles together without completely melting them. This process uses a temperature high enough to allow for the polymer material to burn off leaving a porous structure.
  • the compression strength as well as the porosity of the construct may be controlled by varying the type and the amount of the sacrificial polymer and the sintering time and temperature used. Porosities as high as 90% may be achieved under suitable conditions.
  • the pores in the bioactive glass material range from about 10 microns to about 5100 microns with an average pore size of 100 ⁇ 50 microns, 200 ⁇ 50 microns, 300 ⁇ 50 microns, 400 ⁇ 50 microns, 500 ⁇ 50 microns, 600 ⁇ 50 microns or 700 ⁇ 50 microns.
  • the bioactive glass ceramic can be in the form of a three-dimensional compressible body of loose glass-based fibers in which the fibers comprise one or more glass-formers selected from the group consisting of P2O 5 , S1O2, and B2O3. Some of the fibers have a diameter between about 100 nm and about 10,000 nm, and a length:width aspect ratio of at least about 10.
  • the pH of the bioactive glass can be adjusted as- needed.
  • the body comprises fibers having a diameter between about 100 nm and about 10,000 nm.
  • the especially small diameter of these fibers renders them highly flexible so they form into the compressible body without breaking.
  • the body includes fibers meeting these dimensional requirements in addition to other glass morphologies, such as fibers of other dimensions, spheres, microspheres, particles, ribbons, flakes or the like.
  • the fibers may have a variety of cross section shapes, such as flat, circular, oval, or non-circular.
  • the bioactive glass/collagen mixture may be in the form of a "CBG packable graft", which as defined herein is a loose collagen and 45S5 bioactive glass mixture that becomes moldable when hydrated.
  • the bioactive glass/collagen mixture may be in the form of a "CBG composite,” which as defined herein is collagen and 45S5 bioactive glass that is lyophilized once into a specific shape.
  • the bioactive glass/collagen mixture may be in the form of a "CBG strip," which as defined herein is collagen and 45S5 bioactive glass that is lyophilized into a rectangular shape and undergoes additional processing.
  • CBG strip collagen and 45S5 bioactive glass that is lyophilized into a rectangular shape and undergoes additional processing.
  • the three CBG combination products, CBG packable graft, CBG composite and CBG strip are designed to facilitate the repair of skeletal defects.
  • the CBG products have a three-dimensional network of pores that resembles the structure of human cancellous bone.
  • the three-dimensional pore structure of the CBG products quickly imbibes and retains fluids, making it easy to combine with saline, blood and/or bone marrow aspirate.
  • the CBG products guide the regeneration of bone across a critical defect site into which the product is implanted. New bone forms within the implant when the graft is placed in direct contact with viable host bone. Ultimately, the CBG product is resorbed and remodeled into bone.
  • the CBG products are intended to be used alone or combined with saline, autograft, allograft, blood, or bone marrow aspirate, and are intended for use as a bone void filler to fill voids or gaps of the skeletal system not intrinsic to the stability of the bony structure.
  • the packaging of the CBG products is designed to facilitate such mixing with saline, autograft, allograft, blood, or bone marrow aspirate
  • the CBG product retains shape after hydration with saline, blood or bone marrow.
  • the CBG products are flexible, as shown in FIGS. 6C-D.
  • the CBG product is also intended for use in the treatment of surgically treated osseous defects or osseous defects created from traumatic injury to the bone.
  • the CBG products possess inter-particle spaces to facilitate the integration of liquid (i.e., blood, bone marrow aspirate, etc.) into the structure in less than, e.g., about 3 min.
  • liquid i.e., blood, bone marrow aspirate, etc.
  • the CBG product is provided sterile, non- pyrogenic, and prepared in a double peel package (as shown, e.g., in FIG. 7A-C and FIG. 8) and is intended for a single use by, e.g., surgeons, and preferably, orthopedic surgeons.
  • a packable graft which is a bioresorbable bone graft material that includes a porous and crystalline bioactive glass, such as 45S5 Bioactive Glass (Bioglass®) in combination with collagen.
  • the packable graft are provided sterile, non-pyrogenic, and prepared in double peel packages as intended for single use (FIG. 4).
  • the packable graft includes a bioactive glass that includes approximately 75-95% by weight bioactive glass; approximately 85- 95% by weight bioactive glass; approximately 85-90% by weight bioactive glass; or approximately 85-87% by weight bioactive glass.
  • the packable graft includes a bioactive glass that includes at least approximately 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, or 95% by weight bioactive glass.
  • the packable graft includes bioactive glass that includes approximately 85% by weight bioactive glass, such as 45S5 Bioactive Glass (Bioglass®).
  • the bioactive glass can include approximately 55-65% 1000-2000 um porous glass, approximately 55-62% 1000-2000 um porous glass, approximately 55- 60% 1000-2000 um porous glass, or approximately 57-60% 1000-2000 um porous glass; approximately 10-20% 90-710 um nonporous glass, approximately 10-15% 90- 710 um nonporous glass, approximately 12-14% 90-710 um nonporous glass, or approximately 12-13% 90-710 um nonporous glass; and approximately 10-20% 32-125 um nonporous glass, approximately 10-15% 32-125 um nonporous glass, approximately 12-14% 32-125 um nonporous glass, or approximately 12-13% 32-125 um nonporous glass.
  • the bioactive glass includes approximately 60% 1000 - 2000 um porous glass, approximately 12.5% 90-710 um nonporous glass, and approximately 12.5% 32-125 um nonporous glass.
  • the bioactive glass is not cross-linked.
  • the bioactive glass may consist of amorphous, crystalline, or a mixture of both types of particles or a material possessing both, amorphous and crystalline domains of various sizes ranging from 32 - 2000um.
  • the particles may be porous particles.
  • the composition of the bioactive glass may include SiO 2 - about 45.0 ⁇ 2.0 wt %; Na 2 O - about 24.5 ⁇ 2.0 wt %; CaO - about 24.5 ⁇ 2.0 wt %; and about P 2 O 5 - 6.0 ⁇ 1 .0 wt %.
  • the Packable grafts also include approximately 5-25% by weight collagen; preferably, about 5-20% by weight collagen, more preferably about 10-20% by weight collagen, most preferably about 15% by weight collagen.
  • Collagen may be synthetic or sourced from mammalian or non-mammalian species including rats, humans and fish.
  • high purity type I collagen from bovine hide (manufactured by Devro Pty Ltd., Bathurst, New South Wales, Australia; distributed in the United States by Collagen Solutions, LLC. San Jose, CA) is used according to the preferred embodiments of the present invention.
  • the collagen complies with FDA guidance for Medical Devices Containing Materials Derived from Animal Sources as well as with EU Directive 2003/32/EC.
  • MACROFORM composite which is a bioresorbable bone graft material that includes a porous and crystalline bioactive glass, such as 45S5 Bioactive Glass (Bioglass®)in combination with collagen.
  • the MACROFORM composite include a bioactive glass that includes approximately 75-95% by weight bioactive glass, approximately 80-95% by weight bioactive glass; approximately 85-95% by weight bioactive glass; or approximately 85-90% by weight bioactive glass.
  • the packable graft includes a bioactive glass that includes at least approximately 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, or 95% by weight bioactive glass.
  • the MACROFORM composite include a bioactive glass that includes approximately 90% by weight bioactive glass, such as 45S5 Bioactive Glass (Bioglass®).
  • the bioactive glass can include approximately 55-65% 1000-2000 urn porous glass, approximately 57-65% 1000-2000 urn porous glass, approximately 55- 60% 1000-2000 urn porous glass, or approximately 60-65% 1000-2000 urn porous glass; approximately 10-20% 90-710 urn nonporous glass, approximately 10-15% 90- 710 urn nonporous glass, approximately 12-14% 90-710 urn nonporous glass, or approximately 12-13% 90-710 urn nonporous glass; and approximately 10-20% 32-125 um nonporous glass, approximately 10-15% 32-125 urn nonporous glass, approximately
  • the bioactive glass includes approximately 60%
  • the bioactive glass is not crosslinked.
  • the bioactive glass may consist of amorphous, crystalline, or a mixture of both types of particles or a material possessing both, amorphous and crystalline domains of various sizes ranging from 32 - 2000um.
  • the particles may be porous particles.
  • the composition of the bioactive glass may include SiO 2 - about 45.0 ⁇ 2.0 wt %; Na 2 O - about 24.5 ⁇ 2.0 wt %; CaO - about 24.5
  • the composite also includes approximately 5-25% by weight collagen; preferably, about 5-20% by weight collagen, more preferably about 10-20% by weight collagen, most preferably, approximately 10% by weight collagen.
  • Collagen may be synthetic or sourced from mammalian or non-mammalian species including rats, humans and fish.
  • high purity type I collagen from bovine hide is used according to the preferred embodiments of the present invention.
  • the collagen complies with FDA guidance for Medical Devices Containing Materials Derived from Animal Sources as well as with EU Directive 2003/32/EC.
  • a CBG strip which includes approximately 85-97% by weight bioactive glass; approximately 85-95% by weight bioactive glass; approximately 85-90% by weight bioactive glass; or approximately 85- 87% by weight bioactive glass.
  • the packable graft includes a bioactive glass that includes at least approximately 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, or 97% by weight bioactive glass, such as 45S5 bioactive glass (Bioglass®).
  • the CBG strip includes 95% by weight bioactive glass, such as 45S5 Bioactive Glass (Bioglass®) and collagen.
  • the bioactive glass includes approximately 53.5-73.5% 1000-2000 um porous glass, approximately 60-70% 1000-2000 um porous glass, approximately 60- 65% 1000-2000 um porous glass, or approximately 63-64% 1000-2000 um porous glass; approximately 10-20% 90-710 um nonporous glass, approximately 15-20% 90- 710 um nonporous glass, approximately 15-18% 90-710 um nonporous glass, or approximately 15-16% 90-710 um nonporous glass; and approximately 10-20% 32-125 um nonporous glass, approximately 15-20% 32-125 um nonporous glass, approximately 15-18% 32-125 um nonporous glass, or approximately 15-16% 32-125 um nonporous glass.
  • the bioactive glass includes approximately 63.33% 1000-2000 um porous glass, approximately 15.83% 90-710 um nonporous glass, and approximately 15.83% 32-125 um nonporous glass.
  • the bioactive glass is not crosslinked.
  • the bioactive glass may consist of amorphous, crystalline, or a mixture of both types of particles or a material possessing both, amorphous and crystalline domains of various sizes ranging from 32-2000um.
  • the particles may be porous particles.
  • the composition of the bioactive glass includes SiO 2 - approximately 45.0 ⁇ 2.0 wt %; Na 2 O - approximately 24.5 ⁇ 2.0 wt %, CaO - approximately 24.5 ⁇ 2.0 wt %, and P2O 5 - approximately 6.0 ⁇ 1 .0 wt %.
  • the strip also includes approximately 3-15% by weight collagen; preferably, approximately 5% by weight collagen.
  • Collagen may be synthetic or sourced from mammalian or non-mammalian species including rats, humans and fish.
  • high purity type I collagen from bovine tendon is used according to the preferred embodiments of the present invention.
  • the collagen complies with FDA guidance for Medical Devices Containing Materials Derived from Animal Sources as well as with EU Directive 2003/32/EC.
  • Examples of CBG strips are shown in FIGS. 6A-D. As shown specifically, in FIGS. 6C-D, the CBG strip is very flexible and able to retain shape once hydrated with blood or other fluid.
  • various therapeutic agents including growth factors, antibiotics or the like, and other bioactive materials including proteins and glycosaminoglycans may be added during the manufacturing process of the bioactive glass/collagen mixture and/or products.
  • various therapeutic agents and other bioactive materials including proteins and glycosaminoglycans may be added immediately prior to or concurrently with the implantation of the bioactive glass/collagen mixture and/or products.
  • the CBG packable graft, composite and strips may be packaged for terminally sterilized medical devices.
  • the MACROFORM packable graft, composite and strips may be packaged into a kit.
  • the packaging is easy to open and use in sterile surgical environment.
  • the packaging and product labeling is easy to read.
  • the kit may further include a product insert including directions for use.
  • the packaging for the CBG packable graft, composite and strips includes an inner tray to hold CBG packable graft, composite or strip.
  • the packaging may further include an inner tray lid, such as a foil laminate or Tyvek® to seal the product in the inner tray (see e.g., FIG. 7A).
  • the packaging material and seal areas may be identical. Alternatively, the packaging material and seal areas may be different.
  • Exemplary packaging materials include Polyethylene terephthalate glycol-modified (PETG) tray materials (manufactured by, e.g., Eastman Chemical, SK Chemicals and Artenius Italia).
  • the packaging may also include an outer tray that contains the inner tray and an outer tray lid (FIGS, 7B-C and FIG. 8).
  • the packaging materials and seal areas may be identical or different.
  • both, the inner and outer tray of the packaging is labeled.
  • the CBG products may be available in various shapes and sizes.
  • Some exemplary shapes for the CBG composite product include: 15 mm height x 10 mm diameter; 15 mm height x 15 mm diameter; 50 mm length x 25 mm width x 4 mm height; 50 mm length x 25 mm width x 8 mm height; 100 mm length x 25 mm width x 4 mm height; 100 mm length x 25 mm width x 6 mm height; and 100 mm length x 25 mm width x 8 mm height.
  • the CBG composite product's weight may vary depending upon size as follows: 0.4 - 1 .1 grams for 15 mm height x 10 mm diameter; 1 .2 - 1 .9 grams for 15 mm height x 15 mm diameter; 2.0 - 3.9 grams for 50 mm length x 25 mm width x 4 mm height; 4.0 - 6.9 grams for 50 mm length x 25 mm width x 8 mm height; 4.0 - 6.9 grams for 100 mm length x 25 mm width x 4 mm height; 7.0 - 9.9 grams for 100 mm length x 25 mm width x 6 mm height; and 10.0 - 14.0 grams for 100 mm length x 25 mm width x 8 mm height.
  • the strips may be of varying shapes and sizes.
  • the strips may be: 1 .0 cc (10 mm height x 15 mm diameter), 2.5 cc (15 mm height x 15 mm diameter), 5.0 cc (50 mm length x 25 mm width x 4 mm height), 10.0 cc (50 mm length x 25 mm width x 8 mm height), 10.0 cc (100 mm length x 25 mm width x 4 mm height), 15.0 cc (100 mm length x 25 mm width x 6 mm height), and 20.0 cc (100 mm length x 25 mm width x 8 mm height).
  • the packaging also includes a dispenser box, as shown in FIG. 4D.
  • the dispenser box may be of various shapes and sizes, including 1 .0 cc, 2.5 cc, 5.0 cc, 10.0 cc (short), 10.0 cc (long), 15.0 cc, and 20.0 cc.
  • kits may further include a biopsy needle, such as Jamshidi needle, which is a cylindrical, trephine needle with a tapered cutting tip.
  • a biopsy needle such as Jamshidi needle, which is a cylindrical, trephine needle with a tapered cutting tip.
  • Exemplary biopsy needles were previously described in U.S. Pat. No. 4,356,828, which is incorporated by reference herein in its entirety.
  • the CBG material may be packaged in a syringe, syringe which attaches to a biopsy needle to facilitate hydration with blood or bone marrow.
  • the syringe may have a removable cap to allow delivery of the hydrated material.
  • the combination products described herein may be disposed within a syringe,
  • the syringe may be placed directly in a tray (e.g., inner tray) for packaging into a kit.
  • the syringe may be first sealed in a pouch and then packaged into a kit.
  • Bioactive glass ceramics may be prepared by heating a composition comprising one or more of SiO 2 , CaH(PO 4 ), CaO, P 2 O, Na 2 O, CaCO 3 , Na 2 CO 3 , K 2 CO 3 , MgO, and H 2 BO 3 to a temperature between 1300 and 1500 °C such that the composition may form molten glass.
  • An exemplary composition that can form fibers includes 40-60% SiO 2 , 10-20% CaO, 0-4% P 2 O 5 , and 19-30% NaO.
  • compositions include 45S5, which includes 46.1 mol% SiO 2 , 26.9 mol% Ca), 24.4 mol% Na 2 O and 2.5 mol% P 2 O 5 ; 45S5B1 , which includes 46.1 mol% B 2 O 3 , 26.9 mol% Ca), 24.4 mol% Na 2 O and 2.5 mol% P 2 O 5 ; 58S, which includes 60 mol% SiO 2 , 36 mol% CaO and 4 mol% P 2 O 5 ; and S70C30, which includes 70 mol% SiO 2 and 30 mol% CaO.
  • Another exemplary composition includes 40 mol% SiO 2 , 40 mol% B 2 O 3 , 20 mol% CaO, and 20 mol% Na 2 O.
  • dehydrothermal treatment may involve the removal of water from collagen.
  • Various methods of dehydrothermal treatment of collagen are known in the art.
  • Dehydrothermal treatment generally involves application of moderate heat under vacuum to remove water from the collagen.
  • Crosslinking can result from dehydrothermal treatment by a dehydration reaction in which a hydroxyl group from one collagen molecule is combined with a proton from another collagen molecule. It is noted that in the various aspects and embodiments of the invention, significant crosslinking of the collagen can occur without dehydrothermal treatment.
  • the steps are carried out in succession as follows. Water or an ion-containing solution is first mixed with the collagen and bioactive glass to form a paste. The paste is then freeze-dried to form a composite. Then, the composite is dried, such as by dehydrothermal treatment. It is noted that significant crosslinking of the collagen can occur without any drying step or dehydrothermal treatment step undertaken.
  • Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments.
  • the bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO 4 )3, or any other suitable buffer.
  • the collagen is in the form of fibers suspended in aqueous solution.
  • the bioactive glass is present in a weight ratio of from 80% to 90% in proportion to the total weight of the bioactive glass and the collagen.
  • the weight ratio of bioactive glass may be about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, or about 90% in proportion to the total weight of the bioactive glass and the collagen.
  • the composite is ionically-crosslinked.
  • Incubation of collagen in a solution containing divalent cations is effective to crosslink collagen.
  • the divalent cations can be one or more of Ca 2+ , Mg 2+ , Fe 2+ , Sr 2+ , Cd 2+ , Co 2+ , Mn 2+ , Ni 2+ , and Zn 2+ .
  • the divalent cations may be leached from glass that is submerged in water or an aqueous ion-containing solution.
  • a bioactive glass submerged in water can leach calcium and/or strontium ions.
  • polyvalent (3+ or higher) metal ions may also be released from the glass that is submerged in water or an aqueous ion-containing solution.
  • the polyvalent metal ions may include Al 3+ , Fe 3+ , V 4+ , Ti 4+ and Zr 4+ .
  • the mechanical properties of the composite, or material are tested.
  • the tensile strength may be measured, for example, if the composite is in the form of fibers.
  • Methods of measuring tensile strength are known in the art, such as described in ASTM-D 638, which is incorporated by reference herein in its entirety.
  • the compressive strength, or ability of the composite or material to resist compression may also be measured.
  • Methods of measuring compressive strength are known in the art, such as described in ASTM-D 695, which is incorporated by reference herein in its entirety.
  • the flexural strength of the material may be tested, such as described in Goudouri, et al., "Dental Ceramics/Bioactive Glass Composites: Characterization and Mechanical Properties Investigation” Bioceramics Dev. App. 201 1 , (1 ):1 -4, incorporated by reference in its entirety herein.
  • Another aspect of the invention provides for a method for crosslinking collagen.
  • Water or an ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is freeze-dried to form a composite.
  • the method may further comprise drying the composite, such as by dehydrothermal treatment.
  • the dehydrothermal treatment step is not required, however, for significant crosslinking to occur. These steps may be performed in succession or in any order.
  • the glass may be such that it is capable of releasing divalent cations in the presence of water.
  • Some exemplary glasses include a blend of ionomer glass with a 45S5 bioactive glass and a slurry of a 1 % CaC ⁇ solution at pH 6.5 with a 45S5 bioactive glass.
  • these may be one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , St 2 *, Cd 2+ , Al 3+ , Cr 2+ , Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the steps are carried out in succession as follows. Water or an ion-containing solution is first mixed with collagen and a glass to form a paste. The paste is then freeze-dried to form a composite. After freeze-drying, the composite may optionally be dried, such as by dehydrothermal treatment. The dehydrothermal treatment step is not required, however, for significant crosslinking to occur.
  • Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying, or dehydrothermal treatments.
  • the bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO 4 )3, or any other suitable buffer.
  • collagen is in the form of collagen fibers suspended in aqueous solution.
  • the composite formed in any of the embodiments of this aspect may be ionically-crosslinked.
  • the ionic crosslinking can occur by means of the various methods and embodiments described herein, such as by incubating the composite in bioactive glass.
  • the composite comprises from 60 wt.% to 95 wt.% of the glass, from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
  • Another aspect of the invention provides for a method for crosslinking collagen fibers.
  • Water or an ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is freeze-dried to form a composite.
  • the composite is immersed in water or solutions containing divalent or polyvalent metal ions. The immersion may be from 3 to 24 hours.
  • the composite is freeze-dried.
  • collagen is in the form of fibers suspended in aqueous solution.
  • the method may further comprise drying the composite, such as by dehydrothermal treatment.
  • the dehydrothermal treatment step is not required, however, for significant crosslinking to occur.
  • the glass is capable of releasing divalent cations in the presence of water.
  • Some exemplary divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2+ , Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may be a bioactive glass.
  • the composite may be ionically-crosslinked.
  • Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments.
  • the bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe 2 (SO ) 3 , or any other suitable buffer.
  • the composite comprises from 60 wt.% to 95 wt.% of the glass, from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
  • Another aspect of the invention provides for a method for crosslinking collagen fibers.
  • Water or an ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is freeze-dried to form a composite.
  • the composite is immersed in water or solutions containing divalent or polyvalent metal ions.
  • the composite is freeze-dried and then dried. These steps may be performed in succession or in any order.
  • the method further comprises drying the composite.
  • the drying may be conducted by dehydrothermal treatment.
  • the dehydrothermal treatment step is not required, however, for significant crosslinking to occur.
  • the glass is capable of releasing divalent cations in the presence of water.
  • Some exemplary divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass is a bioactive glass, such as those described in the above aspect of the invention.
  • the mechanical properties of the composite are tested.
  • the ways in which mechanical properties are tested include those discussed in other aspects of the invention.
  • collagen is in the form of collagen fibers suspended in aqueous solution.
  • the immersion of the composite in water or solutions containing divalent or polyvalent metal ions is conducted from 3 to 24 hours.
  • the immersion may be conducted for about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 1 1 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
  • the composite is ionically-crosslinked by any of the various methods described herein, such as by incubating the composite in a solution having divalent cations.
  • An exemplary solution is calcium chloride.
  • the calcium chloride may be in a concentration ranging from 0.1 % to 1 %, such as 0.1 %, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, and 1 .0%.
  • the calcium chloride solution may be at any pH, such as pH 6.5 or pH 7.0.
  • Crosslinking may also be enhanced by adding ionomer glasses, such as TF-325 in powder form.
  • Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization or dehydrothermal treatments.
  • the bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe 2 (SO 4 )3, or any other suitable buffer.
  • the composite comprises from 60 wt.% to 90 wt.% of the glass, from 65 wt.% to 95 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
  • Yet another aspect of the invention provides for a method for crosslinking collagen.
  • An ion-containing solution is mixed with collagen and a glass to form a paste.
  • the paste is transferred to a mold.
  • the paste is freeze-dried to form a composite.
  • the method further comprises drying the composite.
  • the drying may be conducted by dehydrothermal treatment.
  • the dehydrothermal treatment step is not required, however, for significant crosslinking to occur.
  • the glass is capable of releasing divalent cations in the presence of water.
  • Some exemplary divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass is a bioactive glass.
  • the bioactive glass may be one or more of the various bioactive glasses described herein.
  • the bioactive glass may be 45S5.
  • Crosslinking may also be enhanced by adding ionomer glass, such as TF-325 in powder form.
  • Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments.
  • the bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe 2 (SO 4 )3, or any other suitable buffer.
  • the mechanical properties of the composite are tested.
  • the ways in which mechanical properties are tested include those discussed in other aspects of the invention.
  • the collagen may be in the form of collagen particles or fibers suspended in aqueous solution or a dispersion of acid swollen collagen fibers.
  • the immersion of the composite in water or solutions containing divalent or polyvalent metal ions is conducted from 3 to 24 hours.
  • the immersion may be conducted for about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 1 1 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
  • the composite is ionically-crosslinked.
  • the crosslinking may arise from the presence of divalent cations, as discussed above.
  • the composite comprises from 60 wt.% to 95 wt.% of the glass, from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
  • the invention also provides for a mixture of collagen and a glass.
  • the mixture comprises from 60 wt.% to 90 wt.% of the glass.
  • the collagen is crosslinked by the glass.
  • the mixture does not comprise chitosan or an organic crosslinking agent.
  • the mixture further comprises water.
  • the glass may be capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2+ , Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass is a bioactive glass.
  • the composite comprises from 60 wt.% to 90 wt.% of the glass, from 65 wt.% to 95 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
  • the glass is capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may be a bioactive glass in some embodiments of this aspect as well. Crosslinking may also be enhanced by adding ionomer glasses, such as TF-325 in powder form.
  • Another aspect of the invention provides for a crosslinked collagen material consisting of collagen and a glass.
  • the material comprises from 60 wt.% to 97.5 wt.% of the glass.
  • the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
  • the glass is capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may be a bioactive glass in some embodiments of this aspect as well.
  • Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen, water, and a glass.
  • the material may comprise from 60 wt.% to 97.5 wt.% of the glass.
  • the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
  • the glass is capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may be a bioactive glass in some embodiments of this aspect as well. Crosslinking may also be enhanced by adding ionomer glass, such as TF-325 in powder form.
  • Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments.
  • the bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe 2 (SO 4 )3, or any other suitable buffer.
  • Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen, water, ions, and a glass.
  • the material comprises from 60 wt.% to 97.5 wt.% of the glass.
  • the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
  • the glass is capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may be a bioactive glass in some embodiments of this aspect as well.
  • Another aspect of the invention provides for a crosslinked collagen material consisting of collagen fibers and a glass.
  • the material comprises from 60 wt.% to 97.5 wt.% of the glass.
  • the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
  • the glass is capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may be a bioactive glass as well.
  • Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen fibers, water, and a glass.
  • the material comprises from 60 wt.% to 97.5 wt.% of the glass.
  • the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
  • the glass is capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may also be a bioactive glass.
  • Another aspect of the invention provides for a crossl inked collagen material consisting of collagen fibers, water, ions, and a glass.
  • the material comprises from 60 wt.% to 90 wt.% of the glass.
  • the material comprises from 60 wt.% to 97.5 wt.% of the glass.
  • the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass.
  • the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
  • the glass is capable of releasing divalent cations in the presence of water.
  • the divalent and polyvalent cations include one or more of Ca 2+ , Cu 2+ , Mg 2+ , Fe 2+ , Fe 3+ , Sr 2+ , Cd 2+ , Al 3+ , Cr 2 *, Co 2+ , Mn 2+ , Ni 2+ , Sn 2+ , and Zn 2+ .
  • the glass may be a bioactive glass in some embodiments of this aspect as well.
  • a "Packable graft” as defined herein is a loose collagen and 45S5 bioactive glass mixture that becomes moldable when hydrated.
  • control sample "1" was prepared by hydrating 100% collagen with Dl WATER (reverse osmosis deionized water prepared using the Sartorius system) until the material became moldable and then by forming a 2.5cc sphere. The sphere was then soaked in Dl WATER for 24 hours.
  • Dl WATER reverse osmosis deionized water prepared using the Sartorius system
  • test samples "2", “3”, and “4" were prepared by combining 1 -2 mm, 90-710 ⁇ 45S5 bioglass, and 32-125 ⁇ 45S5 bioglass with collagen. The dry materials were then hydrated with varying CaCI 2 solutions and then soaked in Dl WATER for 24 hours.
  • Test samples "5" and "7" were prepared similarly to Samples 2-4 except HCI was used to adjust the pH of the different percent CaC ⁇ solutions to 6.5.
  • Test sample "6" was prepared by replacing 5wt% of the 32-125 ⁇ 45S5 bioactive glass with ionomer glass, in particular ionomer glass powder TF-325. The packable graft was then hydrated and soaked in Dl WATER.
  • Test sample 6 was prepared with the same hydrating and soaking solutions as the control (sample 1 ) and exhibited higher compressive strength because of the presence of the bioactive and ionomer glasses.
  • a "CBG strip” as defined herein is collagen and 45S5 bioactive glass that is lyophilized into a rectangular shape.
  • control Sample A was prepared by making a slurry with collagen and Dl WATER in a 1 :1 ratio by weight. The slurry was then lyophilized and subjected to DHT in molds to form 5 cc strips. The collagen strips were then soaked in Dl WATER for 3 hours and lyophilized once more.
  • Test Sample B was prepared similarly to Sample A, except the soaking solution following DHT was 1 % Fe 2 (SO 4 ) 3 in place of Dl WATER.
  • Test Samples C and E were prepared with a slurry of glass, collagen, and
  • Dl WATER adjusted to a pH of 5.
  • Sample C contained 90 wt% glass and Sample E contained 85 wt% glass.
  • the slurries were then lyophilized and then subjected to DHT to form strips, soaked in Dl WATER for 3 hours and lyophilized once more.
  • Test Sample D was prepared similarly to sample E except the slurry solution was pH adjusted CaCI 2 in place of Dl WATER and HCI and the soaking solution was PBS in place of Dl WATER.
  • Test Sample F was prepared by combining the glass and collagen, hydrating with Dl WATER, and placing the sample into the tray. The tray was then soaked in Dl WATER for 3 hours and lyophilized. Sample E did not undergo DHT.
  • a "plate" shape was used to evaluate the strips on the Shimadzu Mechanical Strength Tester. Tests were conducted under ambient conditions and all samples were tested in accordance with SOP PR-06.06 Mechanical Testing of CBG Product. Stress was applied in a circumferential direction. Specimens were elongated at a rate of 5 mm/min until failure, with the force and extension recorded over time.
  • Samples prepared with bioglass exhibited greater tensile strength than the control that was only crosslinked with DHT.
  • Sample F indicates that the collagen can be crosslinked and a high tensile strength can be achieved without DHT processing.
  • a slurry was prepared by mixing 0.28g of collagen with 4.55ml_ reverse osmosis deionized water and 0.49ml_ 2N HCI. The slurry was mixed until all collagen was saturated. Next, all glass starting with 1 -2mm (1 .68g), then 710-90um (0.42g), then 32-125um (0.42g) was poured into the beaker labeled "slurry" and the components mixed until homogenous.
  • the slurry was then lyophilized in molds to form 5 cc strips.
  • the autoclaved molds were selected based on the desired amount of slurry to be placed in the mold and as per recommendations in the Table below (e.g., 2.5cc mold for making 2.5cc composites). Size of Well Max Amount of
  • the objective of the study was to determine the extent of fluid/blood absorption for the Bioactive Strip, MacroFORM Composite and Packable products.
  • the study was conducted at ambient conditions: 68-74°F and 40-60% relative humidity.
  • Dry weights were taken for each product.
  • the devices were then hydrated with citrated sheep's blood and molded until the entirety of the product was saturated in blood.
  • the hydrated weight was then taken of each sample and a measure of amount of blood absorbed per gram of product was calculated.
  • the MacroFORM products absorbed similar amounts of blood, approximately 0.6 - 0.75 grams of blood per gram of dry product.
  • Samples were evaluated using mercury porosimetry.
  • the process measures porosity by applying pressure to a sample immersed in mercury.
  • the pressure required to inject mercury into the sample is inversely proportional to the size of the pores (MPS).
  • the applicable variables were dependent (percent porosity), independent (device) and lot number),
  • the test was completed after the porosity of the sample was determined. [00178]
  • the average percent porosity for the MacroFORM Composite batches were 79.3% ⁇ 2.32 for lot 1 104H5, 75.9% ⁇ 1 .12 for lot 1 104N4, and 75.3% ⁇ 0.83 for lot 1 104M3.
  • the Table below lists the porosity of each lot and the average and standard deviation of the MacroFORM Composite device.
  • Applicable variables included dependent (Pore Size Distribution and Percent Porosity), Independent (Device) and uncontrolled (shipping and storage conditions).

Abstract

The present invention relates to combination products including bioactive glass and collagen as well as kits comprising the same.

Description

COMBINATION PRODUCTS INCLUDING BIOACTIVE GLASS AND COLLAGEN
AND KITS INCLUDING THE SAME
[0001] This application is a continuation-in-part of U.S. Application No. 13/833,400, filed March 15, 2013, which claims priority under 35 U.S.C. § 1 19 to U.S. Provisional Application No. 61/710,332, filed October 5, 2012, and which is also a continuation-in- part of U.S. Application No. 13/039,627, filed March 3, 201 1 , which claims benefit of U.S. Provisional Application No. 61/310,129, filed March 3, 2010, the entire contents of which are hereby incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Collagen is the main component of connective tissue and is generally found in the body as a triple helix. Collagen is also prevalent in bone. Known methods of crosslinking include introducing disulfide bonds between individual collagen molecules and fibrils. Crosslinked collagen can have enhanced mechanical attributes. The addition of crosslinked collagen to wounded tissue or bone defects may serve to provide structural support. There are various ways to crosslink collagen, such as by UV light and the use of chemical crosslinkers. Herein is provided a novel way to crosslink collagen in a manner that maintains the structure of collagen without introducing toxins that are difficult to remove.
[0003] Bioactive glass was originally developed in 1969 by L. Hench. Additionally bioactive glasses were developed as bone replacement materials, with studies showing that bioactive glass can induce or aid in osteogenesis. Hench et al, J. Biomed. Mater. Res. 5:1 17-141 (1971 ). Bioactive glass can form strong and stable bonds with bone. Piotrowski et al., J. Biomed. Mater. Res. 9:47-61 (1975). Further, bioactive glass is not considered toxic to bone or soft tissue from studies of in vitro and in vivo models. Wilson et al., J. Biomed. Mater. Res. 805-817 (1981 ). Exemplary bioactive glasses known in the art include 45S5, 45S5B1 , 58S, and S70C30. The original bioactive glass, 45S5, is melt-derived. Sol-gel derived glasses have nanopores that allow for increased surface area and bioactivity. [0004] U.S. Patent Application Publication No. 2002/0055143 discloses cement particles UV crosslinked with collagen.
[0005] U.S. Patent No. 8,252,055 discloses crosslinking a collagen mineral containing composition including Bioglass.
SUMMARY OF THE INVENTION
[0006] One aspect of the invention provides for a method for crosslinking collagen. An ion-containing solution is mixed with collagen and a glass to form a paste. The paste is freeze-dried to form a composite.
[0007] Another aspect of the invention provides for a method for crosslinking collagen fibers. Water or an ion-containing solution is mixed with collagen and a glass to form a paste. The paste is freeze-dried to form a composite. The composite is immersed in water or solutions containing divalent or polyvalent metal ions. The composite is freeze-dried.
[0008] Yet another aspect of the invention provides for a method for crosslinking collagen. An ion-containing solution is mixed with collagen and a glass to form a paste. The paste is transferred to a mold. The paste is freeze-dried to form a composite.
[0009] Another aspect of the invention provides for a method for crosslinking collagen fibers. Water or an ion-containing solution is mixed with collagen and a glass to form a paste. The paste is freeze-dried to form a composite. The composite is immersed in water or solutions containing divalent or polyvalent metal ions. The composite is freeze-dried and then dried.
[0010] An aspect provides for a mixture of collagen and a glass. The mixture comprises from 60 wt.% to 90 wt.% of the glass. The collagen is crosslinked by the glass. The mixture does not comprise chitosan or an organic crosslinking agent.
[0011] The invention also provides for a crosslinked collagen material consisting of collagen and a glass. Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen, water, and a glass. Alternatively, the invention provides for a crosslinked collagen material consisting of collagen, an ion-containing solution, and a glass. [0012] The invention also provides for a crosslinked collagen material consisting of collagen fibers and a glass. Alternatively, the invention provides for a crosslinked collagen material consisting of collagen fibers, water, and a glass. Another aspect of the invention provides for a crosslinked collagen material consisting of collagen fibers, an ion-containing solution, and a glass.
[0013] The invention provides for a combination product that includes a porous and nonporous bioactive glass and collagen. In the combination product the bioactive glass may be present in a weight ratio of from 80% to 97% in proportion to the total weight of the bioactive glass and the collagen. The combination product may include from 85 wt.% to 97.5 wt.% of the bioactive glass. The combination product may be in a form of a packable graft. The packable graft may include 75-95 wt.% bioactive glass and 5-25 wt.% collagen. The packable graft may include 85 wt.% bioactive glass and 15 wt.% collagen. In the combination product, the bioactive glass may include 55-65% 1000- 2000 um bioactive glass, 10-20% 90-710 um bioactive glass, and 10-20% 32-125 um bioactive glass. In the combination product the bioactive glass may include 60% 1000- 2000 um bioactive glass, 12.5% 90-710 um bioactive glass, and 12.5% 32-125 um bioactive glass. In the combination product, the 1000-2000 um bioactive glass is porous. The combination product may be in a form of a collagen bioactive glass composite. The composite may include 75-95 wt.% bioactive glass and 5-25 wt.% collagen. The composite may include 90 wt.% bioactive glass and 10 wt.% collagen. The bioactive glass of the composite may include 55-65% 1000-2000 um bioactive glass, 10-20% 90-710 um bioactive glass, and 10-20% 32-125 um bioactive glass. The bioactive glass of the composite may include 60% 1000-2000 um bioactive glass, 15% 90-710 um bioactive glass, and 15% 32-125 um bioactive glass. The 1000-2000 um bioactive glass of the composite is porous. The combination product may be in a form of a strip. The strip may include 85-97 wt.% bioactive glass and 3-15 wt.% collagen. The strip may include 95 wt.% bioactive glass and 5 wt.% collagen. The strip may include 97.5 wt.% bioactive glass and 2.5 wt.% collagen. The bioactive glass of the strip may include 53.5-73.5% 1000-2000 um bioactive glass, 10-20% 90-710 um bioactive glass, 10-20% 32-125 um bioactive glass. The bioactive glass of the strip may include 63.33% 1000-2000 urn bioactive glass, 15.83% 90-710 urn bioactive glass, 15.83% 32-125 um bioactive glass. The 1000-2000 um bioactive glass of the strip is porous. In the combination product, the bioactive glass may include 64.68% 1000-2000 micrometer bioactive glass, 16.16% 90-710 micrometer bioactive glass, 16.16% 32-125 micrometer bioactive glass. The combination product may further include at least one therapeutic agent, protein, or glycosaminoglycan.
[0014] Another aspect provides for a kit comprising a combination product in a form of a packable graft, composite or a strip and a packaging. The packaging may be a double peel packaging. The packaging may include an inner tray, wherein the combination product is contained within the inner tray, an inner tray lid, an outer tray, wherein the inner tray is placed in the outer tray, and an outer tray lid. The kit may further include a dispenser box. The kit may further include a syringe. The combination product may be disposed within the syringe. The syringe may include a removable cap. The syringe may be placed in the inner tray. The kit may include a syringe comprising a removable cap, wherein the syringe is sealed in a pouch.
[0015] Furthermore, the invention provides for a method for ionically crosslinking collagen. The method includes mixing an ion-containing solution with the 10 wt.% collagen and 90 wt.% bioactive glass to form a paste and freeze-drying the paste to form a composite.
BRIEF DESCRIPTIONS OF THE FIGURES
[0016] Figure 1 is a photomicrograph of crosslinked collagen bioactive glass strip composite at 29.9x magnification.
[0017] Figure 2 is a photomicrograph of crosslinked collagen bioactive glass strip composite at 300x magnification.
[0018] Figure 3 depicts a graph of blood absorption of Bioactive Strip, Composite and Packable products.
[0019] Figures 4 A-B are photographs depicting a CBG composite product and its packaging. [0020] Figure 4C is a photograph of the CBG composite product combined with a fluid.
[0021] Figure 4 D depicts a photograph of an exemplary dispenser box.
[0022] Figure 5 depicts a bar graph showing the average porosity of MacroFORM
Composite, and Bioactive Strip Lots.
[0023] Figure 6A is a photograph of the dry form of the exemplary CBG strip placed in its packaging.
[0024] Figure 6B is a photograph of the exemplary CBG strip in its packaging during hydration with blood.
[0025] Figure 6C is a photograph of the exemplary CBG strip in a hydrated state.
[0026] Figure 6D is a photograph of the exemplary CBG strip in a hydrated state.
[0027] Figures 7A-C are photographs of the dry form of the exemplary CBG strip placed in its packaging.
[0028] Figure 8 is a photograph of the exemplary inner and outer trays of the packaging for the CBG strips.
DETAILED DESCRIPTION OF THE INVENTION
[0029] One aspect of the invention provides for a method for crosslinking collagen. An ion-containing solution is mixed with the collagen and bioactive glass to form a paste. The paste is freeze-dried to form a composite. In some embodiments, the method further comprises drying the composite. These steps may be performed in succession or in any order. One way in which the composite may be dried is by dehydrothermal treatment. Significant crosslinking of the collagen can occur without any drying step or dehydrothermal treatment step undertaken. Addition of the drying step or dehydrothermal treatment step can lead to enhanced crosslinking.
[0030] Bioactive glass used in the invention may be melt-derived or sol-gel derived. Depending on their composition, bioactive glasses of the invention may bind to soft tissues, hard tissues, or both soft and hard tissues. The composition of the bioactive glass may be adjusted to modulate the degree of bioactivity. Furthermore, borate may be added to bioactive glass to control the rate of degradation. Additional elements, such as barium, copper, fluorine, silver, zinc, and strontium may be added to bioactive glass to facilitate healthy bone growth or provide other desirable properties. The bioactive glass may be in the form of a particle, a glass sheet, a fiber, a mesh, or any combination of these forms.
[0031] Bioactive glass is capable of bonding to bone, which begins with the exposure of bioactive glass to aqueous solutions. Sodium ions in the glass can exchange with hydronium ions in body fluids, which increases the pH. Calcium and phosphorous ions can migrate from the glass to form a calcium and phosphate-rich surface layer. Borate ions can also migrate from the glass to from a surface layer rich in boron. Strontium ions also can migrate from the glass to form a strontium-rich surface layer. Underlying this surface layer is another layer which becomes increasingly silica rich due to the loss of sodium, calcium, strontium, boron, and/or phosphate ions (U.S. Pat. No. 4,851 ,046). Hydrolysis may then disrupt the Si-O-Si bridges in the silica layer to form silanol groups, which can disrupt the glass network. The glass network is then thought to form a gel in which calcium phosphate from the surface layer accumulates. Mineralization may then occur as calcium phosphate becomes crystalline hydroxyapatite, which effectively mimics the mineral layer of bones.
[0032] Bioactive glass particles, fibers, meshes or sheets may be prepared by a sol- gel method. Methods of preparing such bioactive active glasses are described in Pereira, M. et al., "Bioactive glass and hybrid scaffolds prepared by sol-gel method for bone tissue engineering" Advances in Applied Ceramics, 2005, 104(1 ): 35-42 and in Chen, Q. et al., "A new sol-gel process for producing Na2O-containing bioactive glass ceramics" Acta Biomaterialia, 2010, 6(10):4143-4153.
[0033] The composition can be allowed to solidify. In some embodiments, particles of bioactive glass are sintered to form a porous glass.
[0034] Repeated cooling and reheating may be performed on the solidified or sintered bioactive glass, with or without spinning, to draw the bioactive glass produced into fibers. A glass drawing apparatus may be coupled to the spinner and the source of molten bioactive glass, such as molten bioactive glass present in a crucible, for the formation of bioactive glass fibers. The individual fibers can then be joined to one another, such as by use of an adhesive, to form a mesh. Alternatively, the bioactive glass in molten form may be placed in a cast or mold to form a sheet or another desired shape.
[0035] The bioactive glass particles, fibers, meshes or sheets may further comprise any one or more of adhesives, grafted bone tissue, in vitro-generated bone tissue, collagen, calcium phosphate, stabilizers, antibiotics, antibacterial agents, antimicrobials, drugs, pigments, X-ray contrast media, fillers, and other materials that facilitate grafting of bioactive glass to bone.
[0036] A bioactive glass ceramic material suitable for the present compositions and methods may have silica, sodium, calcium, strontium, phosphorous, and boron present, as well as combinations thereof. In some embodiments, sodium, boron, strontium, and calcium may each be present in the compositions in an amount of about 1 % to about 99%, based on the weight of the bioactive glass ceramic. In further embodiments, sodium, boron, strontium and calcium may each be present in the composition in about 1 %, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In certain embodiments, silica, sodium, boron, and calcium may each be present in the composition in about 5 to about 10%, about 10 to about 15%, about 15 to about 20%, about 20 to about 25%, about 25 to about 30%, about 30 to about 35%, about 35 to about 40%, about 40 to about 45%, about 45 to about 50%, about 50 to about 55%, about 55 to about 60%, about 60 to about 65%, about 65 to about 70%, about 70 to about 75%, about 75 to about 80%, about 80 to about 85%, about 85 to about 90%, about 90 to about 95%, or about 95 to about 99%. Some embodiments may contain substantially one or two of sodium, calcium, strontium, and boron with only traces of the other(s). The term "about" as it relates to the amount of calcium phosphate present in the composition means +/- 0.5%. Thus, about 5% means 5 +/- 0.5%. Divalent cations or ions that may be present in any of the bioactive glasses of this and other aspects of the invention include one or more of iron-ll, iron-Ill, alumina, chromate, cobalt, tin, copper, magnesium, and zinc.
[0037] The bioactive glass materials may further comprise one or more of a silicate, borosilicate, borate, strontium, or calcium, including SrO, CaO, P2O5, SiO2, and B2O3. An exemplary bioactive glass is 45S5, which includes 46.1 mol% SiO2, 26.9 mol% CaO, 24.4 mol% Na2O and 2.5 mol% P2O5. An exemplary borate bioactive glass is 45S5B1 , in which the S1O2 of 45S5 bioactive glass is replaced by B2O3. Other exemplary bioactive glasses include 58S, which includes 60 mol% S1O2, 36 mol% CaO and 4 mol% P2O5, and S70C30, which includes 70 mol% SiO2 and 30 mol% CaO. In any of these or other bioactive glass materials of the invention, SrO may be substituted for CaO.
[0038] The following composition, having a weight % of each element in oxide form in the range indicated, will provide one of several bioactive glass compositions that may be used to form a bioactive glass ceramic:
Figure imgf000010_0001
[0039] In some embodiments, the particles are sintered to form porous particulate made from the bioactive glass particles. In one embodiment, fine particles of the bioactive glass are mixed with a sacrificial polymer and a binder to create a pre-shaped construct (e.g., a block or disk). The construct is then heated under specific conditions that allow a welding of the particles together without completely melting them. This process uses a temperature high enough to allow for the polymer material to burn off leaving a porous structure. The compression strength as well as the porosity of the construct may be controlled by varying the type and the amount of the sacrificial polymer and the sintering time and temperature used. Porosities as high as 90% may be achieved under suitable conditions. The pores in the bioactive glass material range from about 10 microns to about 5100 microns with an average pore size of 100±50 microns, 200±50 microns, 300±50 microns, 400±50 microns, 500±50 microns, 600±50 microns or 700±50 microns.
[0040] The bioactive glass ceramic can be in the form of a three-dimensional compressible body of loose glass-based fibers in which the fibers comprise one or more glass-formers selected from the group consisting of P2O5, S1O2, and B2O3. Some of the fibers have a diameter between about 100 nm and about 10,000 nm, and a length:width aspect ratio of at least about 10. The pH of the bioactive glass can be adjusted as- needed.
[0041] In some embodiments, the body comprises fibers having a diameter between about 100 nm and about 10,000 nm. The especially small diameter of these fibers renders them highly flexible so they form into the compressible body without breaking. In some embodiments the body includes fibers meeting these dimensional requirements in addition to other glass morphologies, such as fibers of other dimensions, spheres, microspheres, particles, ribbons, flakes or the like. The fibers may have a variety of cross section shapes, such as flat, circular, oval, or non-circular.
[0042] In any of the various aspects and embodiments of the invention, the bioactive glass/collagen mixture may be in the form of a "CBG packable graft", which as defined herein is a loose collagen and 45S5 bioactive glass mixture that becomes moldable when hydrated. Alternatively, in any of the various aspects and embodiments of the invention, the bioactive glass/collagen mixture may be in the form of a "CBG composite," which as defined herein is collagen and 45S5 bioactive glass that is lyophilized once into a specific shape. Alternatively, in any of the various aspects and embodiments of the invention, the bioactive glass/collagen mixture may be in the form of a "CBG strip," which as defined herein is collagen and 45S5 bioactive glass that is lyophilized into a rectangular shape and undergoes additional processing.
[0043] The three CBG combination products, CBG packable graft, CBG composite and CBG strip are designed to facilitate the repair of skeletal defects. The CBG products have a three-dimensional network of pores that resembles the structure of human cancellous bone. The three-dimensional pore structure of the CBG products quickly imbibes and retains fluids, making it easy to combine with saline, blood and/or bone marrow aspirate.
[0044] The CBG products guide the regeneration of bone across a critical defect site into which the product is implanted. New bone forms within the implant when the graft is placed in direct contact with viable host bone. Ultimately, the CBG product is resorbed and remodeled into bone.
[0045] In certain embodiments, the CBG products are intended to be used alone or combined with saline, autograft, allograft, blood, or bone marrow aspirate, and are intended for use as a bone void filler to fill voids or gaps of the skeletal system not intrinsic to the stability of the bony structure. Furthermore, the packaging of the CBG products is designed to facilitate such mixing with saline, autograft, allograft, blood, or bone marrow aspirate The CBG product retains shape after hydration with saline, blood or bone marrow. Also, the CBG products are flexible, as shown in FIGS. 6C-D.
[0046] In certain other embodiments, the CBG product is also intended for use in the treatment of surgically treated osseous defects or osseous defects created from traumatic injury to the bone.
[0047] In certain embodiments, the CBG products possess inter-particle spaces to facilitate the integration of liquid (i.e., blood, bone marrow aspirate, etc.) into the structure in less than, e.g., about 3 min.
[0048] Following placement in the bony void or gap (defect), the CBG product is resorbed and replaced with bone during the healing process.
[0049] In preferred embodiments, the CBG product is provided sterile, non- pyrogenic, and prepared in a double peel package (as shown, e.g., in FIG. 7A-C and FIG. 8) and is intended for a single use by, e.g., surgeons, and preferably, orthopedic surgeons.
MacroFORM Packable Graft
[0050] Certain embodiments relate to a packable graft, which is a bioresorbable bone graft material that includes a porous and crystalline bioactive glass, such as 45S5 Bioactive Glass (Bioglass®) in combination with collagen. In preferred embodiments, the packable graft are provided sterile, non-pyrogenic, and prepared in double peel packages as intended for single use (FIG. 4).
[0051] In certain preferred embodiments, the packable graft includes a bioactive glass that includes approximately 75-95% by weight bioactive glass; approximately 85- 95% by weight bioactive glass; approximately 85-90% by weight bioactive glass; or approximately 85-87% by weight bioactive glass. In certain embodiments, the packable graft includes a bioactive glass that includes at least approximately 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, or 95% by weight bioactive glass. In a preferred embodiment, the packable graft includes bioactive glass that includes approximately 85% by weight bioactive glass, such as 45S5 Bioactive Glass (Bioglass®).
[0052] The bioactive glass can include approximately 55-65% 1000-2000 um porous glass, approximately 55-62% 1000-2000 um porous glass, approximately 55- 60% 1000-2000 um porous glass, or approximately 57-60% 1000-2000 um porous glass; approximately 10-20% 90-710 um nonporous glass, approximately 10-15% 90- 710 um nonporous glass, approximately 12-14% 90-710 um nonporous glass, or approximately 12-13% 90-710 um nonporous glass; and approximately 10-20% 32-125 um nonporous glass, approximately 10-15% 32-125 um nonporous glass, approximately 12-14% 32-125 um nonporous glass, or approximately 12-13% 32-125 um nonporous glass. In one preferred embodiment, the bioactive glass includes approximately 60% 1000 - 2000 um porous glass, approximately 12.5% 90-710 um nonporous glass, and approximately 12.5% 32-125 um nonporous glass.
[0053] In certain embodiments, the bioactive glass is not cross-linked.
[0054] In certain embodiments, the bioactive glass may consist of amorphous, crystalline, or a mixture of both types of particles or a material possessing both, amorphous and crystalline domains of various sizes ranging from 32 - 2000um.
[0055] In certain embodiments, the particles may be porous particles.
[0056] In certain preferred embodiments, the composition of the bioactive glass may include SiO2 - about 45.0 ± 2.0 wt %; Na2O - about 24.5 ± 2.0 wt %; CaO - about 24.5 ± 2.0 wt %; and about P2O5 - 6.0 ± 1 .0 wt %. [0057] The Packable grafts also include approximately 5-25% by weight collagen; preferably, about 5-20% by weight collagen, more preferably about 10-20% by weight collagen, most preferably about 15% by weight collagen. Collagen may be synthetic or sourced from mammalian or non-mammalian species including rats, humans and fish. Preferably, high purity type I collagen from bovine hide (manufactured by Devro Pty Ltd., Bathurst, New South Wales, Australia; distributed in the United States by Collagen Solutions, LLC. San Jose, CA) is used according to the preferred embodiments of the present invention. The collagen complies with FDA guidance for Medical Devices Containing Materials Derived from Animal Sources as well as with EU Directive 2003/32/EC.
MACROFORM Composite
[0058] Certain embodiments relate to a MACROFORM composite, which is a bioresorbable bone graft material that includes a porous and crystalline bioactive glass, such as 45S5 Bioactive Glass (Bioglass®)in combination with collagen.
[0059] In certain preferred embodiments, the MACROFORM composite include a bioactive glass that includes approximately 75-95% by weight bioactive glass, approximately 80-95% by weight bioactive glass; approximately 85-95% by weight bioactive glass; or approximately 85-90% by weight bioactive glass. In certain embodiments, the packable graft includes a bioactive glass that includes at least approximately 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, or 95% by weight bioactive glass. In a preferred embodiment, the MACROFORM composite include a bioactive glass that includes approximately 90% by weight bioactive glass, such as 45S5 Bioactive Glass (Bioglass®).
[0060] The bioactive glass can include approximately 55-65% 1000-2000 urn porous glass, approximately 57-65% 1000-2000 urn porous glass, approximately 55- 60% 1000-2000 urn porous glass, or approximately 60-65% 1000-2000 urn porous glass; approximately 10-20% 90-710 urn nonporous glass, approximately 10-15% 90- 710 urn nonporous glass, approximately 12-14% 90-710 urn nonporous glass, or approximately 12-13% 90-710 urn nonporous glass; and approximately 10-20% 32-125 um nonporous glass, approximately 10-15% 32-125 urn nonporous glass, approximately
12-14% 32-125 um nonporous glass, or approximately 12-13% 32-125 um nonporous glass. In a preferred embodiment, the bioactive glass includes approximately 60%
1000-2000 um porous glass, approximately 15% 90-710 um nonporous glass, and approximately 15% 32-125 um nonporous glass.
[0061] In certain embodiments, the bioactive glass is not crosslinked.
[0062] In certain embodiments, the bioactive glass may consist of amorphous, crystalline, or a mixture of both types of particles or a material possessing both, amorphous and crystalline domains of various sizes ranging from 32 - 2000um.
[0063] In certain embodiments, the particles may be porous particles.
[0064] In certain preferred embodiments, the composition of the bioactive glass may include SiO2 - about 45.0 ± 2.0 wt %; Na2O - about 24.5 ± 2.0 wt %; CaO - about 24.5
± 2.0 wt %; and about P2O5 - 6.0 ± 1 .0 wt %.
[0065] The composite also includes approximately 5-25% by weight collagen; preferably, about 5-20% by weight collagen, more preferably about 10-20% by weight collagen, most preferably, approximately 10% by weight collagen. Collagen may be synthetic or sourced from mammalian or non-mammalian species including rats, humans and fish. Preferably, high purity type I collagen from bovine hide (manufactured by Devro Pty Ltd., Bathurst, New South Wales, Australia; distributed in the United States by Collagen Solutions, LLC. San Jose, CA) is used according to the preferred embodiments of the present invention. The collagen complies with FDA guidance for Medical Devices Containing Materials Derived from Animal Sources as well as with EU Directive 2003/32/EC.
CBG Strip
[0066] Certain other embodiments relate to a CBG strip, which includes approximately 85-97% by weight bioactive glass; approximately 85-95% by weight bioactive glass; approximately 85-90% by weight bioactive glass; or approximately 85- 87% by weight bioactive glass. In certain embodiments, the packable graft includes a bioactive glass that includes at least approximately 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, or 97% by weight bioactive glass, such as 45S5 bioactive glass (Bioglass®). In a preferred embodiment, the CBG strip includes 95% by weight bioactive glass, such as 45S5 Bioactive Glass (Bioglass®) and collagen.
[0067] The bioactive glass includes approximately 53.5-73.5% 1000-2000 um porous glass, approximately 60-70% 1000-2000 um porous glass, approximately 60- 65% 1000-2000 um porous glass, or approximately 63-64% 1000-2000 um porous glass; approximately 10-20% 90-710 um nonporous glass, approximately 15-20% 90- 710 um nonporous glass, approximately 15-18% 90-710 um nonporous glass, or approximately 15-16% 90-710 um nonporous glass; and approximately 10-20% 32-125 um nonporous glass, approximately 15-20% 32-125 um nonporous glass, approximately 15-18% 32-125 um nonporous glass, or approximately 15-16% 32-125 um nonporous glass. In certain preferred embodiments, the bioactive glass includes approximately 63.33% 1000-2000 um porous glass, approximately 15.83% 90-710 um nonporous glass, and approximately 15.83% 32-125 um nonporous glass.
[0068] In certain embodiments, the bioactive glass is not crosslinked.
[0069] In certain embodiments, the bioactive glass may consist of amorphous, crystalline, or a mixture of both types of particles or a material possessing both, amorphous and crystalline domains of various sizes ranging from 32-2000um.
[0070] In certain embodiments, the particles may be porous particles.
[0071] The composition of the bioactive glass includes SiO2 - approximately 45.0 ± 2.0 wt %; Na2O - approximately 24.5 ± 2.0 wt %, CaO - approximately 24.5 ± 2.0 wt %, and P2O5 - approximately 6.0 ± 1 .0 wt %.
[0072] The strip also includes approximately 3-15% by weight collagen; preferably, approximately 5% by weight collagen. Collagen may be synthetic or sourced from mammalian or non-mammalian species including rats, humans and fish. Preferably, high purity type I collagen from bovine tendon (manufactured by Southern Lights Biomaterials 163 Tennyson Street, Napier 41 10, New Zealand) is used according to the preferred embodiments of the present invention. The collagen complies with FDA guidance for Medical Devices Containing Materials Derived from Animal Sources as well as with EU Directive 2003/32/EC. [0073] Examples of CBG strips are shown in FIGS. 6A-D. As shown specifically, in FIGS. 6C-D, the CBG strip is very flexible and able to retain shape once hydrated with blood or other fluid.
[0074] In any of the various aspects and embodiments of the invention, various therapeutic agents, including growth factors, antibiotics or the like, and other bioactive materials including proteins and glycosaminoglycans may be added during the manufacturing process of the bioactive glass/collagen mixture and/or products. Alternatively, various therapeutic agents and other bioactive materials including proteins and glycosaminoglycans may be added immediately prior to or concurrently with the implantation of the bioactive glass/collagen mixture and/or products.
KITS
[0075] The CBG packable graft, composite and strips may be packaged for terminally sterilized medical devices.
[0076] In certain embodiments, the MACROFORM packable graft, composite and strips may be packaged into a kit. The packaging is easy to open and use in sterile surgical environment. The packaging and product labeling is easy to read. The kit may further include a product insert including directions for use.
[0077] In certain preferred embodiments, as shown in FIGS 7A-C and FIG 8, the packaging for the CBG packable graft, composite and strips includes an inner tray to hold CBG packable graft, composite or strip. The packaging may further include an inner tray lid, such as a foil laminate or Tyvek® to seal the product in the inner tray (see e.g., FIG. 7A). The packaging material and seal areas may be identical. Alternatively, the packaging material and seal areas may be different. Exemplary packaging materials include Polyethylene terephthalate glycol-modified (PETG) tray materials (manufactured by, e.g., Eastman Chemical, SK Chemicals and Artenius Italia). Although, PETG is the most common and preferred material for use as the packaging material, other tray materials may also be used. For example, the lids may be made from foil laminates or Tyvek, depending on the mode of sterilization to be employed for the CBG products of the present invention. [0078] The packaging may also include an outer tray that contains the inner tray and an outer tray lid (FIGS, 7B-C and FIG. 8). The packaging materials and seal areas may be identical or different.
[0079] In certain embodiments, both, the inner and outer tray of the packaging is labeled.
[0080] The CBG products may be available in various shapes and sizes.
[0081] Some exemplary shapes for the CBG composite product include: 15 mm height x 10 mm diameter; 15 mm height x 15 mm diameter; 50 mm length x 25 mm width x 4 mm height; 50 mm length x 25 mm width x 8 mm height; 100 mm length x 25 mm width x 4 mm height; 100 mm length x 25 mm width x 6 mm height; and 100 mm length x 25 mm width x 8 mm height.
[0082] The CBG composite product's weight may vary depending upon size as follows: 0.4 - 1 .1 grams for 15 mm height x 10 mm diameter; 1 .2 - 1 .9 grams for 15 mm height x 15 mm diameter; 2.0 - 3.9 grams for 50 mm length x 25 mm width x 4 mm height; 4.0 - 6.9 grams for 50 mm length x 25 mm width x 8 mm height; 4.0 - 6.9 grams for 100 mm length x 25 mm width x 4 mm height; 7.0 - 9.9 grams for 100 mm length x 25 mm width x 6 mm height; and 10.0 - 14.0 grams for 100 mm length x 25 mm width x 8 mm height.
[0083] The strips may be of varying shapes and sizes. For example, the strips may be: 1 .0 cc (10 mm height x 15 mm diameter), 2.5 cc (15 mm height x 15 mm diameter), 5.0 cc (50 mm length x 25 mm width x 4 mm height), 10.0 cc (50 mm length x 25 mm width x 8 mm height), 10.0 cc (100 mm length x 25 mm width x 4 mm height), 15.0 cc (100 mm length x 25 mm width x 6 mm height), and 20.0 cc (100 mm length x 25 mm width x 8 mm height).
[0084] The product weight for the CBG strips will vary depending upon size as follows: 1 .0 cc: 0.6 - 1 .5 grams, 2.5 cc: 2.0 - 2.9 grams, 5.0 cc: 4.1 - 6.5 grams, 10.0S cc: 7.8 - 1 1 .1 grams, 10.0L cc: 7.8 - 1 1 .1 grams, 15.0 cc: 12.5 - 15.3 grams, and 20.0 cc: 13.8 - 16.7 grams. [0085] In certain embodiments, the packaging also includes a dispenser box, as shown in FIG. 4D. The dispenser box may be of various shapes and sizes, including 1 .0 cc, 2.5 cc, 5.0 cc, 10.0 cc (short), 10.0 cc (long), 15.0 cc, and 20.0 cc.
[0086] In certain embodiments, the kits may further include a biopsy needle, such as Jamshidi needle, which is a cylindrical, trephine needle with a tapered cutting tip. Exemplary biopsy needles were previously described in U.S. Pat. No. 4,356,828, which is incorporated by reference herein in its entirety.
[0087] In certain embodiments, the CBG material may be packaged in a syringe, syringe which attaches to a biopsy needle to facilitate hydration with blood or bone marrow. The syringe may have a removable cap to allow delivery of the hydrated material.
[0088] In certain embodiments, the combination products described herein may be disposed within a syringe, The syringe may be placed directly in a tray (e.g., inner tray) for packaging into a kit. Alternatively, the syringe may be first sealed in a pouch and then packaged into a kit.
[0089] Bioactive glass ceramics may be prepared by heating a composition comprising one or more of SiO2, CaH(PO4), CaO, P2O, Na2O, CaCO3, Na2CO3, K2CO3, MgO, and H2BO3 to a temperature between 1300 and 1500 °C such that the composition may form molten glass. An exemplary composition that can form fibers includes 40-60% SiO2, 10-20% CaO, 0-4% P2O5, and 19-30% NaO. Other exemplary compositions include 45S5, which includes 46.1 mol% SiO2, 26.9 mol% Ca), 24.4 mol% Na2O and 2.5 mol% P2O5; 45S5B1 , which includes 46.1 mol% B2O3, 26.9 mol% Ca), 24.4 mol% Na2O and 2.5 mol% P2O5; 58S, which includes 60 mol% SiO2, 36 mol% CaO and 4 mol% P2O5; and S70C30, which includes 70 mol% SiO2 and 30 mol% CaO. Another exemplary composition includes 40 mol% SiO2, 40 mol% B2O3, 20 mol% CaO, and 20 mol% Na2O.
[0090] In this and other aspects of the invention, dehydrothermal treatment may involve the removal of water from collagen. Various methods of dehydrothermal treatment of collagen are known in the art. Dehydrothermal treatment generally involves application of moderate heat under vacuum to remove water from the collagen. Crosslinking can result from dehydrothermal treatment by a dehydration reaction in which a hydroxyl group from one collagen molecule is combined with a proton from another collagen molecule. It is noted that in the various aspects and embodiments of the invention, significant crosslinking of the collagen can occur without dehydrothermal treatment.
[0091] In some embodiments, the steps are carried out in succession as follows. Water or an ion-containing solution is first mixed with the collagen and bioactive glass to form a paste. The paste is then freeze-dried to form a composite. Then, the composite is dried, such as by dehydrothermal treatment. It is noted that significant crosslinking of the collagen can occur without any drying step or dehydrothermal treatment step undertaken.
[0092] Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments. The bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO4)3, or any other suitable buffer.
[0093] The collagen is in the form of fibers suspended in aqueous solution. In some embodiments, the bioactive glass is present in a weight ratio of from 80% to 90% in proportion to the total weight of the bioactive glass and the collagen. The weight ratio of bioactive glass may be about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, or about 90% in proportion to the total weight of the bioactive glass and the collagen.
[0094] In some embodiments of this and other aspects of the invention, the composite is ionically-crosslinked. Incubation of collagen in a solution containing divalent cations is effective to crosslink collagen. The divalent cations can be one or more of Ca2+, Mg2+, Fe2+, Sr2+, Cd2+, Co2+, Mn2+, Ni2+, and Zn2+. The divalent cations may be leached from glass that is submerged in water or an aqueous ion-containing solution. For example, a bioactive glass submerged in water can leach calcium and/or strontium ions.
[0095] In certain other embodiments, polyvalent (3+ or higher) metal ions may also be released from the glass that is submerged in water or an aqueous ion-containing solution. The polyvalent metal ions may include Al3+, Fe3+, V4+, Ti4+ and Zr4+.
[0096] In some embodiments of this and other aspects of the invention, the mechanical properties of the composite, or material, are tested. For instance, the tensile strength may be measured, for example, if the composite is in the form of fibers. Methods of measuring tensile strength are known in the art, such as described in ASTM-D 638, which is incorporated by reference herein in its entirety. The compressive strength, or ability of the composite or material to resist compression, may also be measured. Methods of measuring compressive strength are known in the art, such as described in ASTM-D 695, which is incorporated by reference herein in its entirety. Also, the flexural strength of the material may be tested, such as described in Goudouri, et al., "Dental Ceramics/Bioactive Glass Composites: Characterization and Mechanical Properties Investigation" Bioceramics Dev. App. 201 1 , (1 ):1 -4, incorporated by reference in its entirety herein.
[0097] Another aspect of the invention provides for a method for crosslinking collagen. Water or an ion-containing solution is mixed with collagen and a glass to form a paste. The paste is freeze-dried to form a composite. The method may further comprise drying the composite, such as by dehydrothermal treatment. The dehydrothermal treatment step is not required, however, for significant crosslinking to occur. These steps may be performed in succession or in any order. The glass may be such that it is capable of releasing divalent cations in the presence of water. Some exemplary glasses include a blend of ionomer glass with a 45S5 bioactive glass and a slurry of a 1 % CaC^ solution at pH 6.5 with a 45S5 bioactive glass. If the glass releases divalent or polyvalent cations, these may be one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, St2*, Cd2+, Al3+, Cr2+, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+.
[0098] In some embodiments, the steps are carried out in succession as follows. Water or an ion-containing solution is first mixed with collagen and a glass to form a paste. The paste is then freeze-dried to form a composite. After freeze-drying, the composite may optionally be dried, such as by dehydrothermal treatment. The dehydrothermal treatment step is not required, however, for significant crosslinking to occur.
[0099] Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying, or dehydrothermal treatments. The bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO4)3, or any other suitable buffer.
[00100] In some embodiments, collagen is in the form of collagen fibers suspended in aqueous solution.
[00101] The composite formed in any of the embodiments of this aspect may be ionically-crosslinked. The ionic crosslinking can occur by means of the various methods and embodiments described herein, such as by incubating the composite in bioactive glass. In some embodiments, the composite comprises from 60 wt.% to 95 wt.% of the glass, from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In some embodiments, the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
[00102] Another aspect of the invention provides for a method for crosslinking collagen fibers. Water or an ion-containing solution is mixed with collagen and a glass to form a paste. The paste is freeze-dried to form a composite. The composite is immersed in water or solutions containing divalent or polyvalent metal ions. The immersion may be from 3 to 24 hours. The composite is freeze-dried. In some embodiments, collagen is in the form of fibers suspended in aqueous solution. These steps may be performed in succession or in any order.
[00103] The method may further comprise drying the composite, such as by dehydrothermal treatment. The dehydrothermal treatment step is not required, however, for significant crosslinking to occur. In some embodiments, the glass is capable of releasing divalent cations in the presence of water. Some exemplary divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2+, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may be a bioactive glass. The composite may be ionically-crosslinked.
[00104] Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments. The bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO )3, or any other suitable buffer.
[00105] In some embodiments, the composite comprises from 60 wt.% to 95 wt.% of the glass, from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In some embodiments, the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
[00106] Another aspect of the invention provides for a method for crosslinking collagen fibers. Water or an ion-containing solution is mixed with collagen and a glass to form a paste. The paste is freeze-dried to form a composite. The composite is immersed in water or solutions containing divalent or polyvalent metal ions. The composite is freeze-dried and then dried. These steps may be performed in succession or in any order.
[00107] In some embodiments of this aspect, the method further comprises drying the composite. The drying may be conducted by dehydrothermal treatment. The dehydrothermal treatment step is not required, however, for significant crosslinking to occur. In some embodiments, the glass is capable of releasing divalent cations in the presence of water. Some exemplary divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+.
[00108] In some embodiments, the glass is a bioactive glass, such as those described in the above aspect of the invention.
[00109] In some embodiments, the mechanical properties of the composite are tested. The ways in which mechanical properties are tested include those discussed in other aspects of the invention.
[00110] In some embodiments, collagen is in the form of collagen fibers suspended in aqueous solution.
[00111] In some embodiments, the immersion of the composite in water or solutions containing divalent or polyvalent metal ions is conducted from 3 to 24 hours. The immersion may be conducted for about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 1 1 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
[00112] In some embodiments of this aspect, the composite is ionically-crosslinked by any of the various methods described herein, such as by incubating the composite in a solution having divalent cations. An exemplary solution is calcium chloride. The calcium chloride may be in a concentration ranging from 0.1 % to 1 %, such as 0.1 %, 0.2%, 0.25%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, and 1 .0%. The calcium chloride solution may be at any pH, such as pH 6.5 or pH 7.0. Crosslinking may also be enhanced by adding ionomer glasses, such as TF-325 in powder form.
[00113] Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization or dehydrothermal treatments. The bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO4)3, or any other suitable buffer.
[00114] In some embodiments of this aspect, the composite comprises from 60 wt.% to 90 wt.% of the glass, from 65 wt.% to 95 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In some embodiments, the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
[00115] Yet another aspect of the invention provides for a method for crosslinking collagen. An ion-containing solution is mixed with collagen and a glass to form a paste. The paste is transferred to a mold. The paste is freeze-dried to form a composite.
[00116] In some embodiments of this aspect, the method further comprises drying the composite. The drying may be conducted by dehydrothermal treatment. The dehydrothermal treatment step is not required, however, for significant crosslinking to occur. In some embodiments, the glass is capable of releasing divalent cations in the presence of water. Some exemplary divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+.
[00117] In some embodiments, the glass is a bioactive glass. The bioactive glass may be one or more of the various bioactive glasses described herein. In some embodiments, the bioactive glass may be 45S5. Crosslinking may also be enhanced by adding ionomer glass, such as TF-325 in powder form.
[00118] Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments. The bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO4)3, or any other suitable buffer.
[00119] In some embodiments, the mechanical properties of the composite are tested. The ways in which mechanical properties are tested include those discussed in other aspects of the invention.
[00120] The collagen may be in the form of collagen particles or fibers suspended in aqueous solution or a dispersion of acid swollen collagen fibers. [00121] In some embodiments, the immersion of the composite in water or solutions containing divalent or polyvalent metal ions is conducted from 3 to 24 hours. The immersion may be conducted for about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 1 1 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
[00122] In some embodiments of this aspect, the composite is ionically-crosslinked. The crosslinking may arise from the presence of divalent cations, as discussed above.
[00123] In some embodiments of this aspect, the composite comprises from 60 wt.% to 95 wt.% of the glass, from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In some embodiments, the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
[00124] The invention also provides for a mixture of collagen and a glass. The mixture comprises from 60 wt.% to 90 wt.% of the glass. The collagen is crosslinked by the glass. The mixture does not comprise chitosan or an organic crosslinking agent. In some embodiments of this aspect, the mixture further comprises water. The glass may be capable of releasing divalent cations in the presence of water. In some embodiments, the divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2+, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. In some embodiments, the glass is a bioactive glass.
[00125] In some embodiments of this aspect, the composite comprises from 60 wt.% to 90 wt.% of the glass, from 65 wt.% to 95 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In some embodiments, the weight ratio of the bioactive glass in the composite may be about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, or about 95%.
[00126] In some embodiments, the glass is capable of releasing divalent cations in the presence of water. The divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may be a bioactive glass in some embodiments of this aspect as well. Crosslinking may also be enhanced by adding ionomer glasses, such as TF-325 in powder form.
[00127] Another aspect of the invention provides for a crosslinked collagen material consisting of collagen and a glass. The material comprises from 60 wt.% to 97.5 wt.% of the glass. In any of the embodiments of this aspect, the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
[00128] In some embodiments, the glass is capable of releasing divalent cations in the presence of water. The divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may be a bioactive glass in some embodiments of this aspect as well.
[00129] Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen, water, and a glass. The material may comprise from 60 wt.% to 97.5 wt.% of the glass. Alternatively, the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In any of the embodiments of this aspect, the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
[00130] In some embodiments, the glass is capable of releasing divalent cations in the presence of water. The divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may be a bioactive glass in some embodiments of this aspect as well. Crosslinking may also be enhanced by adding ionomer glass, such as TF-325 in powder form.
[00131] Optional soaking steps may be undertaken before and/or after one or more of each of the lyophilization, freeze-drying or dehydrothermal treatments. The bioactive glass, collagen, pastes, and/or composites may be soaked in solutions that include reverse osmosis deionized water, PBS, Fe2(SO4)3, or any other suitable buffer.
[00132] Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen, water, ions, and a glass. The material comprises from 60 wt.% to 97.5 wt.% of the glass. Alternatively, the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In any of the embodiments of this aspect, the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
[00133] In some embodiments, the glass is capable of releasing divalent cations in the presence of water. The divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may be a bioactive glass in some embodiments of this aspect as well.
[00134] Another aspect of the invention provides for a crosslinked collagen material consisting of collagen fibers and a glass. The material comprises from 60 wt.% to 97.5 wt.% of the glass. Alternatively, the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In any of the embodiments of this aspect, the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
[00135] In some embodiments, the glass is capable of releasing divalent cations in the presence of water. The divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may be a bioactive glass as well.
[00136] Yet another aspect of the invention provides for a crosslinked collagen material consisting of collagen fibers, water, and a glass. The material comprises from 60 wt.% to 97.5 wt.% of the glass. Alternatively, the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In any of the embodiments of this aspect, the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight. [00137] In some embodiments, the glass is capable of releasing divalent cations in the presence of water. The divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may also be a bioactive glass.
[00138] Another aspect of the invention provides for a crossl inked collagen material consisting of collagen fibers, water, ions, and a glass. The material comprises from 60 wt.% to 90 wt.% of the glass.
[00139] The material comprises from 60 wt.% to 97.5 wt.% of the glass. Alternatively, the material may comprise from 65 wt.% to 90 wt.% of the glass, from 70 wt.% to 90 wt.% of the glass, from 75 wt.% to 90 wt.% of the glass, or from 80 wt.% to 90 wt.% of the glass. In any of the embodiments of this aspect, the material comprises about 60%, about 61 %, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71 %, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81 %, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91 %, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, or about 97.5% of the glass by weight.
[00140] In some embodiments, the glass is capable of releasing divalent cations in the presence of water. The divalent and polyvalent cations include one or more of Ca2+, Cu2+, Mg2+, Fe2+, Fe3+, Sr2+, Cd2+, Al3+, Cr2*, Co2+, Mn2+, Ni2+, Sn2+, and Zn2+. The glass may be a bioactive glass in some embodiments of this aspect as well.
EXAMPLE 1
Preparation of Packable graft
[00141] A "Packable graft" as defined herein is a loose collagen and 45S5 bioactive glass mixture that becomes moldable when hydrated.
[00142] The control sample "1 " was prepared by hydrating 100% collagen with Dl WATER (reverse osmosis deionized water prepared using the Sartorius system) until the material became moldable and then by forming a 2.5cc sphere. The sphere was then soaked in Dl WATER for 24 hours.
[00143] The test samples "2", "3", and "4" were prepared by combining 1 -2 mm, 90-710 μιτι 45S5 bioglass, and 32-125 μιτι 45S5 bioglass with collagen. The dry materials were then hydrated with varying CaCI2 solutions and then soaked in Dl WATER for 24 hours.
[00144] Test samples "5" and "7" were prepared similarly to Samples 2-4 except HCI was used to adjust the pH of the different percent CaC^ solutions to 6.5.
[00145] Test sample "6" was prepared by replacing 5wt% of the 32-125μηη 45S5 bioactive glass with ionomer glass, in particular ionomer glass powder TF-325. The packable graft was then hydrated and soaked in Dl WATER.
[00146] The samples were evaluated on the Shimadzu Mechanical Strength Tester using compressive plates and a 1 kN Load cell. Tests were conducted under ambient conditions and all samples were tested in accordance with SOP PR-06.06 Mechanical Testing of CBG Product. The indenter displacement was set to 25 mm with a rate of 15 mm/min. The load was released when a max strength of 900 N or a max stroke of 30 mm was obtained.
[00147] The following table illustrates the composition and the compressive strength of the Packable graft samples that were evaluated.
Figure imgf000031_0001
[00148] The data in Table 1 indicates that after soaking, packable graft containing bioactive glass is stronger than a packable graft containing only collagen (control sample 1 ). The data for test samples 3-5 and 7 indicates that the increasing concentration of Ca2+ ions in the hydration solution increases the compressive strength.
Test sample 6 was prepared with the same hydrating and soaking solutions as the control (sample 1 ) and exhibited higher compressive strength because of the presence of the bioactive and ionomer glasses.
[00149] Samples prepared with bioglass and hydrated with various calcium chloride solutions exhibited ionic crosslinking when soaked for 24 hours in Dl WATER.
EXAMPLE 2
Preparation of CBG Strips
[00150] A "CBG strip" as defined herein is collagen and 45S5 bioactive glass that is lyophilized into a rectangular shape.
[00151] The control Sample A was prepared by making a slurry with collagen and Dl WATER in a 1 :1 ratio by weight. The slurry was then lyophilized and subjected to DHT in molds to form 5 cc strips. The collagen strips were then soaked in Dl WATER for 3 hours and lyophilized once more.
[00152] Test Sample B was prepared similarly to Sample A, except the soaking solution following DHT was 1 % Fe2(SO4)3 in place of Dl WATER.
[00153] Test Samples C and E were prepared with a slurry of glass, collagen, and
Dl WATER adjusted to a pH of 5. Sample C contained 90 wt% glass and Sample E contained 85 wt% glass. The slurries were then lyophilized and then subjected to DHT to form strips, soaked in Dl WATER for 3 hours and lyophilized once more.
[00154] Test Sample D was prepared similarly to sample E except the slurry solution was pH adjusted CaCI2 in place of Dl WATER and HCI and the soaking solution was PBS in place of Dl WATER.
[00155] Test Sample F was prepared by combining the glass and collagen, hydrating with Dl WATER, and placing the sample into the tray. The tray was then soaked in Dl WATER for 3 hours and lyophilized. Sample E did not undergo DHT.
[00156] A "plate" shape was used to evaluate the strips on the Shimadzu Mechanical Strength Tester. Tests were conducted under ambient conditions and all samples were tested in accordance with SOP PR-06.06 Mechanical Testing of CBG Product. Stress was applied in a circumferential direction. Specimens were elongated at a rate of 5 mm/min until failure, with the force and extension recorded over time.
[00157] The following table illustrates the composition and the tensile strength of the CBG Strip samples that were evaluated. Sample A is the control.
Figure imgf000033_0001
[00158] The following bulk densities were obtained for CBG strips:
Figure imgf000033_0002
[00159] The control Sample A, was crosslinked using DHT processing. Therefore the increased tensile properties observed in the other Samples B through F can be attributed to ionic crosslinking. The tensile strength of Sample B when compared to the control indicates that ionic crosslinking occurred between the Fe3+ (aq) and the collagen fibers. Samples C and E exhibited higher tensile strengths than the control (Sample A). The compressive strength of Sample F indicates that CBG Strips can be crosslinked without DHT processing.
[00160] Samples prepared with bioglass exhibited greater tensile strength than the control that was only crosslinked with DHT. Sample F indicates that the collagen can be crosslinked and a high tensile strength can be achieved without DHT processing.
Example 3
Preparation of CBG Composite
[00161] Materials: collagen, Bioglass® (32-125 μπτι, 90-710 μπτι, and 1 -2mm), reverse osmosis deionized water, and 2N HCI.
[00162] A slurry was prepared by mixing 0.28g of collagen with 4.55ml_ reverse osmosis deionized water and 0.49ml_ 2N HCI. The slurry was mixed until all collagen was saturated. Next, all glass starting with 1 -2mm (1 .68g), then 710-90um (0.42g), then 32-125um (0.42g) was poured into the beaker labeled "slurry" and the components mixed until homogenous.
[00163] The slurry was then lyophilized in molds to form 5 cc strips. The autoclaved molds were selected based on the desired amount of slurry to be placed in the mold and as per recommendations in the Table below (e.g., 2.5cc mold for making 2.5cc composites). Size of Well Max Amount of
Slurry Per Mold
0.5cc 234cc
1 cc 350cc
2.5cc 240cc
5cc 480cc
6cc 240cc
8cc 360cc
10cc 480cc
[00164] Following the lyophilization procedure, the molds were transferred into a clean room inside of a clean bag.
[00165] Next, molds were sealed, labeled and packaged.
Example 4
Fluid Absorption
[00166] The objective of the study was to determine the extent of fluid/blood absorption for the Bioactive Strip, MacroFORM Composite and Packable products. The study was conducted at ambient conditions: 68-74°F and 40-60% relative humidity.
[00167] The following materials were used for the study: 5cc Bioactive Strip, 2.5cc MacroFORM Composite, and 5cc MacroFORM Packable Morsels.
[00168] Dry weights were taken for each product. The devices were then hydrated with citrated sheep's blood and molded until the entirety of the product was saturated in blood. The hydrated weight was then taken of each sample and a measure of amount of blood absorbed per gram of product was calculated.
[00169] The results of absorption test are show in the Table below and illustrated in FIG. 3. [00170] Table - Average Blood Absorption
Figure imgf000036_0001
[00171] The MacroFORM products absorbed similar amounts of blood, approximately 0.6 - 0.75 grams of blood per gram of dry product.
Example 5
Porosity Study of CBG Composite
[00172] A porosity study was conducted in order to determine the porosity of the MacroFORM Composite.
[00173] Three samples of MacroFORM Composite from 3 separate lots (sample A, sample B and sample C).
[00174] Samples were evaluated using mercury porosimetry. The process measures porosity by applying pressure to a sample immersed in mercury. The pressure required to inject mercury into the sample is inversely proportional to the size of the pores (MPS). The applicable variables were dependent (percent porosity), independent (device) and lot number),
[00175] Mercury parameters were as follows: Adv. Contact Angle: 130.000 degrees; Hg Surface Tension: 485.000 dynes/cm; Rec. Contact Angle: 130.000 degrees; and Hg Density: 13.5335 g/mL.
[00176] Samples were loaded into penetrometer. The penetrometer was sealed and placed in a low pressure port. The penetrometer's cup and stem were backfilled with mercury. Excess mercury was drained.
[00177] The test was completed after the porosity of the sample was determined. [00178] The average percent porosity for the MacroFORM Composite batches were 79.3% ± 2.32 for lot 1 104H5, 75.9% ± 1 .12 for lot 1 104N4, and 75.3% ± 0.83 for lot 1 104M3. The Table below lists the porosity of each lot and the average and standard deviation of the MacroFORM Composite device.
[00179] Table - Porosity of MacroFORM Composite Lots
Figure imgf000037_0001
[00180] The results are illustrated in FIG. 5.
[00181] The porosity measured in these devices facilitates the absorption of water or other fluids through capillary action.
Example 6
Porosity Study of Bioactive Strip
[00182] A study was conducted in order to determine the porosity of a Bioactive Strip. The testing was conducted by Micromeritics Pharmaceutical Services (MPS) in Norcross, GA.
[00183] 3 test samples from 3 separate lots were used in the study. Specifically, 3 NovaBone Bioactive Strip lots (1008P4, 1008P7, and 1008R1 ) were used. The tests protocols were developed and all testing was conducted by MPS (Norcross, GA).
[00184] Samples were evaluated using mercury porosimetry. The process measures porosity by applying pressure to a sample immersed in mercury. The pressure required to inject mercury into the sample is inversely proportional to the size of the pores (MPS). [00185] Mercury Parameters included Adv. Contact Angle: 130.000 degrees; Hg Surface Tension: 485.000 dynes/cm; Rec. Contact Angle: 130.000 degrees; and Hg Density: 13.5335 g/mL.
[00186] Applicable variables included dependent (Pore Size Distribution and Percent Porosity), Independent (Device) and uncontrolled (shipping and storage conditions).
[00187] Samples were loaded into penetrometer. The penetrometer was sealed and placed in a low pressure port. The penetrometer's cup and stem were backfilled with mercury. The excess mercury was drained. The test was completed after the porosity of the sample was determined.
[00188] The Table below shows results of the porosity study of the Bioactive strips.
[00189] Table - Porosity of Bioactive Strip I Lots
Figure imgf000038_0001
[00190] The average percent porosity for the Bioactive Strip batches were 63.0% ± 1 .09 for 1008P4, 64.1 % ± 0.66 for 1008P7, and 63.4% ± 1 .80 for 1008R1 . These results are illustrated in FIG. 5. There were no significant differences in percent porosity between Bioactive Strip Lots
Example 7
Tensile Strength Study of Bioactive Strip [00191] A tensile strength study was conducted to test the resistance of the bioactive strip to a force tending to tear it apart, measured as the maximum tension the material can withstand without tearing.
[00192] Samples of bioactive strips were hydrated and soaked in reagent grade water before testing. The samples were then placed into the grips and tested at 5mm/min until a 50% break was detected.
[00193] The tensile stress data for bioactive strip devices in provided in the Table below.
Figure imgf000039_0001
[00194] The results show that the CBG material is a strong material and can withstand stress even though it is porous. In addition, the strip can bend and flex, as shown in FIGS. 6C-D.
[00195] Throughout this specification various indications have been given as preferred and alternative embodiments of the invention. However, the foregoing detailed description is to be regarded as illustrative rather than limiting and the invention is not limited to any one of the preferred embodiments. It should be understood that it is the appended claims, including all equivalents that are intended to define the spirit and scope of this invention.

Claims

1 . A combination product comprising a porous and nonporous bioactive glass and collagen.
2. The combination product of claim 1 , wherein the bioactive glass is present in a weight ratio of from 80% to 97% in proportion to the total weight of the bioactive glass and the collagen.
3. The combination product of claim 1 , wherein the combination product comprises from 85 wt.% to 97.5 wt.% of the bioactive glass.
4. The combination product of any of claims 1 -3, wherein the combination product is in a form of a packable graft.
5. The combination product of claim 4, wherein the packable graft comprise 75- 95 wt.% bioactive glass and 5-25 wt.% collagen.
6. The combination product of claim 4, wherein the packable graft comprise 85 wt.% bioactive glass and 15 wt.% collagen.
7. The combination product of any of claims 1 -6, wherein the bioactive glass comprises 55-65% 1000-2000 um bioactive glass, 10-20% 90-710 um bioactive glass, and 10-20% 32-125 um bioactive glass.
8. The combination product of any of claims 1 -6, wherein the bioactive glass comprises 60% 1000-2000 um bioactive glass, 12.5% 90-710 um bioactive glass, and 12.5% 32-125 um bioactive glass.
9. The combination product of any of claims 1 -8, wherein the 1000-2000 um bioactive glass is porous.
10. The combination product of claim 1 , wherein the combination product is in a form of a collagen bioactive glass composite.
1 1 . The combination product of claim 10, wherein the composite comprises 75- 95 wt.% bioactive glass and 5-25 wt.% collagen.
12. The combination product of any of claims 10-1 1 , wherein the composite comprises 90 wt.% bioactive glass and 10 wt.% collagen.
13. The combination product of any of claims 10-12, wherein the bioactive glass comprises wherein the bioactive glass comprises 55-65% 1000-2000 um bioactive glass, 10-20% 90-710 um bioactive glass, and 10-20% 32-125 um bioactive glass.
14. The combination product of any of claims 10-13, wherein the bioactive glass comprises 60% 1000-2000 um bioactive glass, 15% 90-710 um bioactive glass, and 15% 32-125 um bioactive glass.
15. The combination product of any of claims 10-14, wherein the 1000-2000 um bioactive glass is porous.
16. The combination product of claim 1 , wherein the combination product is in a form of a strip.
17. The combination product of claim 16, wherein the strip comprises 85-97 wt.% bioactive glass and 3-15 wt.% collagen.
18. The combination product of any of claims 16-17, wherein the strip comprises 95 wt.% bioactive glass and 5 wt.% collagen.
19. The combination product of any of claims 16-18, wherein the strip comprises 97.5 wt.% bioactive glass and 2.5 wt.% collagen.
20. The combination product of any of claims 16-19, wherein the bioactive glass comprises 53.5-73.5% 1000-2000 um bioactive glass, 10-20% 90-710 um bioactive glass, 10-20% 32-125 um bioactive glass.
21 . The combination product of any of claims 16-20, wherein the bioactive glass comprises 63.33% 1000-2000 um bioactive glass, 15.83% 90-710 um bioactive glass, 15.83% 32-125 um bioactive glass.
22. The combination product of any of claims 16-21 , wherein the 1000-2000 um bioactive glass is porous.
23. The combination product of any of claims 16-22, wherein the bioactive glass comprises 64.68% 1000-2000 micrometer bioactive glass, 16.16% 90-710 micrometer bioactive glass, 16.16% 32-125 micrometer bioactive glass.
24. The combination product of claim 23, wherein the 1000-2000 urn bioactive glass is porous.
25. The combination product of any of claims 1 -24, further comprising at least one therapeutic agent, protein, or glycosaminoglycan.
26. A kit comprising the combination product of any of claims 1 -25 and a packaging.
27. The kit of claim 26, wherein the packaging is a double peel packaging.
28. The kit of any of claims 25-27, wherein the packaging comprises an inner tray, wherein the combination product is contained within the inner tray, an inner tray lid, an outer tray, wherein the inner tray is placed in the outer tray, and an outer tray lid.
29. The kit of any of claims 25-28, further comprising a dispenser box.
30. The kit of any of claims 25-29, further comprising a syringe.
31 . The kit of any of claims 25-30, wherein the combination product is disposed within the syringe.
32. The kit of any of claims 30-31 , wherein the syringe comprises a removable cap.
33. The kit of any of claims 30-32, wherein the syringe is placed in the inner tray.
34. The kit of any of claims 24-29, further comprising a syringe comprising a removable cap, wherein the syringe is sealed in a pouch.
35. A method for ionically crosslinking collagen comprising mixing an ion-containing solution with the 10 wt.% collagen and 90 wt.% bioactive glass to form a paste; and
freeze-drying the paste to form a composite.
PCT/US2014/032035 2014-03-27 2014-03-27 Bioactive glass and collagen combination products and kits WO2015147834A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2943837A CA2943837A1 (en) 2014-03-27 2014-03-27 Combination products including bioactive glass and collagen and kits including the same
AU2014388329A AU2014388329B2 (en) 2014-03-27 2014-03-27 Bioactive glass and collagen combination products and kits
EP14886709.6A EP3122392A4 (en) 2014-03-27 2014-03-27 Bioactive glass and collagen combination products and kits
PCT/US2014/032035 WO2015147834A1 (en) 2014-03-27 2014-03-27 Bioactive glass and collagen combination products and kits

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/032035 WO2015147834A1 (en) 2014-03-27 2014-03-27 Bioactive glass and collagen combination products and kits

Publications (2)

Publication Number Publication Date
WO2015147834A1 true WO2015147834A1 (en) 2015-10-01
WO2015147834A8 WO2015147834A8 (en) 2016-11-24

Family

ID=54196151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/032035 WO2015147834A1 (en) 2014-03-27 2014-03-27 Bioactive glass and collagen combination products and kits

Country Status (4)

Country Link
EP (1) EP3122392A4 (en)
AU (1) AU2014388329B2 (en)
CA (1) CA2943837A1 (en)
WO (1) WO2015147834A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238507B2 (en) 2015-01-12 2019-03-26 Surgentec, Llc Bone graft delivery system and method for using same
US10687828B2 (en) 2018-04-13 2020-06-23 Surgentec, Llc Bone graft delivery system and method for using same
US11116647B2 (en) 2018-04-13 2021-09-14 Surgentec, Llc Bone graft delivery system and method for using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035741A1 (en) * 2010-08-05 2012-02-09 Collagen Matrix, Inc. Self-expandable biopolymer-mineral composite
US20130331898A1 (en) * 2012-06-11 2013-12-12 Jevon Nyemscek Bioactive Bone Graft Substitutes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040765A2 (en) * 2006-06-29 2009-04-01 Orthovita, INC. Bioactive bone graft substitute
AU2011223652B2 (en) * 2010-03-03 2015-01-29 Novabone Products, Llc Devices and methods for the regeneration of bony defects
US9144629B2 (en) * 2010-03-03 2015-09-29 Novabone Products, Llc Ionically crosslinked materials and methods for production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035741A1 (en) * 2010-08-05 2012-02-09 Collagen Matrix, Inc. Self-expandable biopolymer-mineral composite
US20130331898A1 (en) * 2012-06-11 2013-12-12 Jevon Nyemscek Bioactive Bone Graft Substitutes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3122392A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238507B2 (en) 2015-01-12 2019-03-26 Surgentec, Llc Bone graft delivery system and method for using same
US11116646B2 (en) 2015-01-12 2021-09-14 Surgentec, Llc Bone graft delivery system and method for using same
US10687828B2 (en) 2018-04-13 2020-06-23 Surgentec, Llc Bone graft delivery system and method for using same
US11116647B2 (en) 2018-04-13 2021-09-14 Surgentec, Llc Bone graft delivery system and method for using same

Also Published As

Publication number Publication date
CA2943837A1 (en) 2015-10-01
EP3122392A4 (en) 2017-11-15
AU2014388329B2 (en) 2019-03-14
EP3122392A1 (en) 2017-02-01
WO2015147834A8 (en) 2016-11-24
AU2014388329A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
US9199032B2 (en) System and kit for delivering collagen bioglass composite bone grafting materials for regenerating hard tissues
US9198936B2 (en) Devices and methods for the regeneration of bony defects
US8460686B2 (en) Bioactive bone graft substitute
Khoshakhlagh et al. Development and characterization of a bioglass/chitosan composite as an injectable bone substitute
US9199006B2 (en) Combination products including bioactive glass and collagen and kits including the same
US9144629B2 (en) Ionically crosslinked materials and methods for production
US20130202670A1 (en) Bioactive antibacterial bone graft materials containing silver
AU2014388329B2 (en) Bioactive glass and collagen combination products and kits
KR101429857B1 (en) Method for manufacturing composite bilayer fiber mat for bone hemorrhage application
AU2013327018B2 (en) Production of novel ionically crosslinked materials
AU2018246310A1 (en) Carrier composition for bone substitute materials
US20200139004A1 (en) Method for coating calcium silicate for preparing bone grafting material having improved biocompatibility
WO2010001328A2 (en) Bioresorbable and flexible membranes exhibiting asymmetric osteoconductive behavior in both faces
AU2014388246A1 (en) Kit for delivering bone grafting materials
Jiang study of bone-like hydroxyapatite/polyamino acid com posite materials for their biological properties and effects on the reconstruction of long bone defects

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14886709

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2943837

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2014886709

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014886709

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014388329

Country of ref document: AU

Date of ref document: 20140327

Kind code of ref document: A